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Neutrophil mobilization, recruitment and clearance must be tightly regulated as over-exuberant 
neutrophilic inflammation is implicated in the pathology of chronic diseases, including asthma. 
Efforts to target neutrophils therapeutically have failed to consider their pleiotropic functions 
and the implications of disrupting fundamental regulatory pathways that govern their turnover 
during homeostasis and inflammation. Using the house dust mite (HDM) model of allergic 
airways disease, we demonstrate that neutrophil depletion unexpectedly resulted in exacerbated 
TH2 inflammation, epithelial remodelling and airway resistance. Mechanistically, this was 
attributable to a striking increase in systemic G-CSF concentrations, which are ordinarily 
negatively regulated in the periphery by transmigrated lung neutrophils. Intriguingly, we found 
that increased G-CSF augmented allergic sensitization in HDM exposed animals by directly 
acting on airway ILC2s to elicit cytokine production. Moreover, increased systemic G-CSF 
promoted expansion of bone marrow monocyte progenitor populations, which resulted in 
enhanced antigen presentation by an augmented peripheral monocyte-derived dendritic cell 
pool.   By modelling the effects of neutrophil depletion, our studies have therefore uncovered 
previously unappreciated roles for G-CSF in modulating ILC2 function and antigen 
presentation. More broadly, they highlight an unexpected regulatory role for neutrophils in 









Neutrophils are essential components of the body’s immune surveillance and host defence 
owing to their capacity to readily eliminate invading pathogens. However, due to their 
considerable destructive capacity and potential to cause damage to healthy tissue, it is critical 
that neutrophil homeostasis is tightly regulated. Neutrophil homeostasis is maintained by a fine 
balance between granulopoiesis, bone marrow storage and release, intravascular margination, 
and ensuing clearance and destruction. The principle regulator of granulopoiesis at steady-state 
is granulocyte colony stimulating factor (G-CSF) / CSF3, with mice lacking the G-CSF 
receptor shown to be severely neutropenic (1–4). Following stress or an inflammatory insult, 
G-CSF and an array of other mediators, such as ELR+ CXC chemokines, are increased and 
function to further promote granulopoiesis and neutrophil recruitment to a tissue (5, 6). 
However, it is critical that this neutrophilic inflammation is tightly regulated and efficiently 
resolved and a homeostatic state restored. Increasingly, there is a growing comprehension for 
the prominent role neutrophils play in regulating their own  turnover both during homeostasis 
and inflammation (7, 8).  
Over-exuberant and persistent neutrophilic responses have been implicated in the pathology of 
an array of chronic diseases including chronic obstructive pulmonary disease, cystic fibrosis 
and asthma. In the context of asthma, elevated neutrophil numbers are associated with 
enhanced severity of disease, impaired lung function, diminished responsiveness to 
corticosteroids, exacerbations and fatality (8–14). However, manipulation of neutrophilic 
inflammation in a clinical setting has been disappointing and failed to ameliorate disease 
pathology (15–21). One potential explanation for this is that strategies seeking to reduce 
neutrophilic inflammation may inadvertently disrupt regulatory functions performed by 
neutrophils.   
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In this study, we demonstrate that chronic, systemic depletion of neutrophils in a house dust 
mite (HDM) murine model of allergic airways disease unexpectedly resulted in exacerbated 
TH2 inflammation, augmented mucus production and increased airway resistance. Central to 
this augmented inflammation in neutrophil-depleted animals was a striking increase in G-CSF 
concentrations, which arose due to a failure of apoptotic neutrophils to trigger a negative 
feedback IL-23 – IL-17 – G-CSF regulatory axis in the periphery, classically designed to limit 
neutrophil production and mobilization from the bone marrow. In the context of our allergic 
airways disease model, the accumulated G-CSF directly potentiated allergen sensitization at 
early time points by promoting TH2 cytokine production by type 2 innate lymphoid cells 
(ILC2s) and acting on bone marrow progenitors to drive monocytosis. This monocytosis 
consequently resulted in augmented antigen presentation by monocyte-derived dendritic cells. 
Thus, we highlight unappreciated roles for G-CSF in promoting ILC2 function and antigen 


















HDM administration elicits a neutrophilic inflammation in the lung and airways of mice. 
Our well-established HDM model of allergic airways disease (Supplementary Fig. 1A) (22) 
provokes a mixed granulocytic inflammation with prominent neutrophilia. In this model, a 
robust increase in neutrophil numbers and percentages in the lung (Supplementary Fig. 1B and 
C, respectively) and airways (Supplementary Fig. 1D and E, respectively) were observed from 
1 week of HDM exposure and persisted until 3 weeks – by which time eosinophils were the 
prominent granulocyte (Supplementary Fig. 1B-E). The elevated neutrophilic inflammation 
observed in HDM treated animals coincided with increased expression levels and protein 
concentrations of classical ELR+ CXC chemokine CXCL1/KC (Supplementary Fig. 1F-H) and 
neutrophil granulopoiesis regulator G-CSF (Supplementary Fig. 1I-K). Neutrophil-derived 
proteases myeloperoxidase (MPO; Supplementary Fig. 2A and B) and metalloproteinase-9 
(MMP-9; Supplementary Fig. 2C and D) are often used as a clinical surrogate for neutrophilic 
inflammation, and levels were indeed found to be elevated in the lung and airways of HDM 
exposed mice. Whilst MPO levels temporally correlated with neutrophilic infiltrate, MMP-9 
levels in the airways continued to increase when neutrophilia had stabilized, likely reflective 
of the multitude of cellular sources of this protease.  
 
Neutrophil depletion exacerbates TH2 inflammation and airway remodelling in HDM exposed 
mice. 
To interrogate the role of neutrophils in our model of allergic airways disease, mice were 
administered an anti-Ly6G (1A8) neutrophil-depleting antibody (23). Differential 1A8 dosing 
regimens were utilized to assess the optimal strategy to deplete neutrophils in mice exposed to 
HDM (Supplementary Fig. 3A), and a previously reported (24) flow cytometry gating protocol 
was employed and modified to identify neutrophils independently of their Ly6G expression 
(Supplementary Fig. 3B) – with neutrophils defined as CD11b+ CD11clo, F480- and 
6 
 
Ly6Cintermediate. A single intraperitoneal administration of 100 µg 1A8 was sufficient to 
completely ablate neutrophil numbers in the lung (Supplementary Fig. 3C and E), airways 
(Supplementary Fig. 3D and E), blood (Supplementary Fig. 3F) and spleen (Supplementary 
Fig. 3G) 24 hrs after a single HDM exposure, with neutrophil numbers in the bone marrow 
(Supplementary Fig. 3H) also partially reduced. When this dosing regimen was employed 
throughout the 3 week duration of the HDM allergic airways disease model (Fig. 1A; 
Supplementary Fig. 3I), a consistent reduction in neutrophil numbers was observed at all time 
points in the lung (Fig. 1B), airways (Fig. 1C) and blood (Supplementary Fig. 3J) relative to 
mice treated with an IgG2a isotype control antibody (2A3). However, depletion of bone 
marrow neutrophils was not apparent at later time points (Supplementary Fig. 3K). The anti-
Ly6G 1A8 antibody has become the preferential strategy to deplete neutrophils (23), owing to 
its purported selective expression by these cells (25, 26). The neutrophil specificity of Ly6G 
expression is further supported by the Catchup Ly6G reporter mice, though low transgene 
activity was reported in a small number of eosinophils within this study (27). In our hands, 
Ly6G expression was largely absent on lymphocytes and monocytes, but low levels were 
detectable on a subset of eosinophils in the bone marrow, blood and lungs of PBS and HDM 
treated mice (Supplementary Fig. 4A-C). However, 1A8 administration selectively depleted 
neutrophils in HDM treated mice, with no effect on numbers of eosinophils and lymphocyte 
numbers, whilst monocytes were surprisingly increased in HDM/1A8 treated animals 
(Supplementary Fig. 4D-F). A marginal reduction in lung eosinophil numbers was, however, 
observed in PBS mice administered 1A8 (Supplementary Fig. 4F). 
The hallmark clinical features of allergic airways disease are established within our model by 
3 weeks of HDM exposure (22). At this time point, despite the substantial reduction in 
neutrophil numbers in 1A8 treated HDM-exposed mice, these animals actually exhibited an 
increase in total cell numbers in their lungs (Fig. 1D), whereas total numbers in the airways 
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were modestly elevated, albeit not significantly relative to control animals (Supplementary Fig. 
5A). The increase in pulmonary inflammation in HDM exposed neutrophil-depleted mice was 
clearly visible by observation of haematoxylin and eosin stained lung sections (Fig. 1E). We 
next sought to determine the nature of the populations that must be elevated in HDM treated 
neutrophil-depleted mice to account for the increase in total inflammation despite the loss of 
neutrophils. HDM-exposed neutrophil-depleted mice displayed increased eosinophils in their 
lungs (Fig. 1F) and airways (Supplementary Fig. 5B) relative to control treated mice 
administered HDM, although this again failed to reach significance in the airways. 
Furthermore, the number of CD4+ TH2 cells in both the lungs (Fig. 1G and H) and airways 
(Supplementary Fig. 5C) were significantly elevated in neutrophil-depleted mice relative to 
control animals after 3 weeks of HDM administration. In keeping with greater TH2 
inflammation in neutrophil depleted animals after 3 weeks of HDM exposure, was a significant 
increase in classical type 2 antibodies, with serum levels of both total (Supplementary Fig. 5D) 
and HDM-specific (Fig. 1I) IgE and IgG1 being elevated compared to 2A3 control animals.  
Observation of haematoxylin and eosin stained lung sections (Fig. 1E) revealed that many of 
the airways of HDM-exposed neutrophil depleted mice were plugged with mucus. 
Accordingly, 1A8-treated HDM exposed mice exhibited increased lung tissue expression of 
the major airway mucin Muc5ac (Supplementary Fig. 5E) with an associated increase in airway 
MUC5AC protein (Supplementary Fig. 5F) relative to 2A3/HDM animals. IL-13 is a major 
instigator of epithelial MUC5AC production within our model of allergic airways disease, and 
accordingly IL-13 concentrations were elevated in the BALF of neutrophil depleted mice 
exposed to HDM (Supplementary Fig. 5G), in keeping with the augmented TH2 response within 
this group. Furthermore, BALF IL-13 concentrations showed a significant correlation with 
MUC5AC protein levels across HDM groups (Supplementary Fig. 5H). In keeping with airway 
obstruction and plugging by mucus, the neutrophil-depleted HDM treated animals exhibited an 
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increase in baseline airway resistance relative to 2A3/HDM controls (Supplementary Fig. 5I), 
with airway resistance correlating with BALF MUC5AC concentrations (Supplementary Fig. 
5J). Changes in lung function of HDM exposed mice following neutrophil depletion were, 
however, restricted to baseline airway resistance, with no differences detectable in airway 
hyperresponsiveness to increasing doses of methacholine relative to 2A3/HDM mice 
(Supplementary Fig. 6).  
An early increase in ILC2-derived TH2 cytokines supports the augmented type 2 inflammation 
observed in neutrophil-depleted mice administered HDM.  
Given the prominent effect of neutrophil depletion on antigen-specific T cell responses and 
type 2 antibody generation, we questioned the potential role of neutrophils in regulating 
allergen sensitization at early time points after HDM exposure when neutrophil numbers were 
at their peak (Fig. 2A). TH2 cytokines are of fundamental importance in driving the type 2 
inflammation and associated antibody responses in allergen models of allergic airways disease 
(28). Accordingly, levels of prototypic TH2 cytokines IL-4, IL-5 and IL-13 were significantly 
increased in the airways of neutrophil-depleted mice relative to controls after 1 week of HDM 
exposure, both in terms of protein levels in BAL fluid (Fig. 2B) and Il4, Il5 and Il13 message 
in cells derived from the airways (Supplementary Fig. 7A). This phenotype was conserved in 
lung tissue, albeit less pronounced, at the level of protein (Supplementary Fig. 7B) and 
transcript (Supplementary Fig. 7C). We next sought to ascertain the cellular source of the 
elevated TH2 cytokines in neutrophil depleted animals at 1 week of HDM exposure. Lung 
epithelial (CD45- EpCAM+), endothelial (CD45- EpCAM- CD31+) and leukocytes (CD45+) 
were isolated via fluorescence-activated cell sorting (FACS) from mice administered PBS or 
HDM for 1 week (Supplementary Fig. 8A) to assess the gene expression of TH2 cytokines. Il4, 
Il5 and Il13 message were only detected in the leukocyte population and were increased upon 
HDM challenge (Supplementary Fig. 8B). ILC2s and CD4+ TH2 cells are classically 
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acknowledged as primary sources of TH2 cytokines in allergen models of allergic airways 
disease (28), and assessment of IL-13 gfp-reporter mice (29) administered HDM for 1 week 
demonstrated that ILC2s were the prominent source of this cytokine at this early time point 
(Supplementary Fig. 8C).  
 
Subsequently, ILC2s and CD4+ T cells were isolated by FACS (Supplementary Fig. 9) from 
the airways (Fig. 2C) and lungs (Supplementary Fig. 10) of control and neutrophil-depleted 
mice challenged with HDM for 1 week and assessed for expression of genes encoding TH2 
cytokines. At this early time point, CD4+ T cells were the prominent source of IL-4 and 
expression was significantly elevated in cells derived from the lungs of neutrophil-depleted 
animals (Supplementary Fig. 10). Conversely, ILC2s were clearly the primary source of IL-5 
and IL-13 (Fig. 2C and Supplementary Fig. 10) and their levels were strikingly elevated in 
airway ILC2s derived from neutrophil-depleted animals (Fig. 2C), in keeping with the 
prominent increase in levels of these cytokines in BAL fluid of these mice. Supportive of these 
findings, the master transcriptional regulator of TH2 cytokine production, GATA-3, showed 
elevated mRNA expression in lung CD4+ T cells (Supplementary Fig. 10) and airway ILC2s 
(Fig. 2C) derived from neutrophil-depleted mice. Intracellular cytokine staining and flow 
cytometry analysis supported these assertions, since whilst the total number of lung and airway 
ILC2s (Supplementary Fig. 11A)  and the proportion (Supplementary Fig. 11B and C)  and 
number (Fig. 2D and Supplementary Fig. 11D-F)  of ILC2s producing IL-13 or IL-5 were not 
consistently elevated in neutrophil-depleted animals administered HDM, the amount of 
cytokines the ILC2s produced on a per cell basis (as adjudged by assessment of geometric 
mean) were significantly elevated (Fig. 2E and Supplementary Fig. 11D-F).  
Elevated monocyte-derived dendritic cells and ensuing antigen presentation in HDM exposed 
neutrophil-depleted mice as a consequence of perturbations in bone marrow progenitor pools. 
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In addition to a TH2 milieu, antigen sampling and presentation by dendritic cells is central to 
allergen sensitization and establishment of a type 2 adaptive response in models of allergic 
airways disease. Concomitant with an increase in ILC2-derived TH2 cytokines in neutrophil 
depleted mice administered HDM for 1 week was a significant increase in lung Ly6Clow and 
Ly6Chigh monocytes (Fig. 3A). Whilst this increase was most pronounced in neutrophil-
depleted mice given HDM, it was also apparent in neutrophil-depleted PBS treated animals. 
This increase in monocyte populations in the lungs of HDM administered neutrophil-depleted 
animals was clearly apparent in precision cut lung slices (PCLS) stained for monocyte marker 
CD115 (Supplementary Fig. 12A). Subsequently, neutrophil-depleted animals also presented 
with an increase in lung monocyte-derived dendritic cells (moDCs) that was again most 
pronounced in those animals administered HDM for 1 week (Fig. 3B). Surprisingly, this 
phenotype was not restricted to moDCs, with a significant increase in lung CD11b+ 
conventional dendritic cells (cDCs) and CD103+ cDCs (Supplementary Fig. 12B) also 
observed in neutrophil-depleted mice.  
Activation and migration of DCs to draining lymph nodes and ensuing priming of allergen-
specific T cell responses is integral to allergen sensitization. In the HDM model, moDCs and 
CD11b+ cDCs are integral to transporting antigen to draining mediastinal lymph nodes (MLNs) 
(28, 30). Numbers of total and activated moDCs (Fig. 3C and D) and CD11b+ cDCs 
(Supplementary Fig. 12C and D) were increased in the MLNs of neutrophil-depleted animals 
administered HDM. To ascertain whether antigen presentation was augmented in neutrophil-
depleted animals exposed to HDM, 2A3 and 1A8 treated mice were administered HDM for 1 
week, with Alexa Fluor-488 tagged ovalbumin (OVA) administered concomitantly with the 
final dose of allergen (Fig. 3E). Importantly, numbers of OVA+ moDCs in neutrophil-depleted 
mice were also significantly elevated in MLNs (Fig. 3F), demonstrating that they were 
effectively transporting antigen to localized lymph nodes. Whilst the same trend was observed 
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with OVA+ CD11b+ cDCs (Supplementary Fig. 12E), the increase in neutrophil-depleted 
animals did not reach statistical significance. Supportive of the assertion of increased antigen 
presentation in HDM treated neutrophil depleted mice, MLN T cells from these animals 
expressed higher levels of activation markers ICOS (Supplementary Fig. 12F) and PD1 
(Supplementary Fig. 12G) and showed greater proliferation (Supplementary Fig. 12H). Thus, 
enhanced antigen presentation in the context of an augmented TH2 cytokine environment 
observed in neutrophil depleted animals during allergen sensitization at 1 week of HDM 
exposure is conducive to the elevated TH2 inflammation seen at later time points.  
To rationalize the accumulation of monocyte populations and ensuing moDCs in the lungs of 
neutrophil depleted mice, we assessed lung concentrations of classical monocyte chemokines 
CCL2 and CX3CL1 after 1 week of HDM exposure. Whilst HDM administration resulted in an 
increase in concentrations of CCL2 and CX3CL1, these chemokines were not further elevated 
in mice depleted of neutrophils and could not therefore account for the tissue monocytosis 
observed in these animals (Supplementary Fig. 13A). Analysis of PCLS revealed increased 
intra-vascular pools of monocytes in neutrophil depleted HDM exposed animals 
(Supplementary Fig. 12A). Accordingly, flow cytometry analysis demonstrated that neutrophil 
depletion resulted in increased numbers of blood Ly6Clow and Ly6Chigh monocytes – in both 
PBS and HDM treated animals (Fig. 4A) – thus providing a greater circulating pool of 
monocytes to extravasate into the lung in response to localized chemokine gradients. 
Subsequently, we questioned whether alteration in bone marrow progenitor pools could 
account for systemic changes in monocyte numbers following neutrophil depletion. 
Accordingly, the percentage of monocyte dendritic cell progenitors (MDPs) (31, 32), defined 
as CD115+, Lineage-, c-Kit+ and FLT-3+ (Supplementary Fig. 13B), were shown to be elevated 
in the bone marrow of neutrophil depleted mice after 1 week of HDM exposure (Fig. 4B). 
Recently, it has been suggested that MDPs differentiate into common dendritic cell progenitor 
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cells (CDPs) (32), which are the first committed dendritic cell progenitor to give rise to the 
cDC subsets that were also shown to be universally elevated in neutrophil depleted mice. 
Consequently, the percentage of CDPs, defined as CD115+, Lineage-, c-Kit-, FLT-3+, CD11b- 
and CD11c- (Supplementary Fig. 13B), were also shown to be elevated in neutrophil depleted 
animals (Fig. 4B). Thus neutrophil depletion gives rise to increased MDPs and CDPs in the 
bone marrow, which ultimately drives elevated monocyte and DC populations in the lung.  
A dysregulated IL-23 – IL-17 – G-CSF axis in neutrophil depleted mice.  
We next sought to ascertain what mediator/s was driving the augmented progenitor pools in 
the bone marrow of neutrophil depleted animals and the ensuing increase in lung monocytes 
and DCs. A proteome profiler array was used to semi-quantitatively assess broad changes in 
cytokines, chemokines and proteases in serum of control and neutrophil depleted mice after 1 
week of HDM administration. Whilst differential levels of various mediators were observed 
via proteome profiler analysis, a striking increase in G-CSF in neutrophil depleted animals was 
particularly noteworthy (Supplementary Fig. 14). This was deemed to be especially pertinent 
given that CSF3R, the G-CSF receptor, is expressed on MDPs and CDPs (33), and that an 
increase in monocytes has been reported in neutropenic patients administered G-CSF to 
promote granulopoiesis (34). Subsequently, serum, lung homogenate and BALF G-CSF levels 
were assessed by ELISA and demonstrated to be strikingly elevated in both PBS and HDM 
treated mice depleted of neutrophils (Fig. 4C). The increase in G-CSF concentration did not 
simply reflect a reduced internalization of the G-CSF following ablation of neutrophils, since 
lung Csf3 gene expression was elevated in neutrophil depleted mice (Fig. 4D).  
 
Previous studies have demonstrated that G-CSF expression is prominently controlled by IL-17 
(35–37), with IL-17 derived from tissue resident T cell populations central to G-CSF regulation 
during homeostasis (38, 39). It was noteworthy therefore that the proteome profiler revealed 
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an increase in IL-17 levels in HDM-exposed neutrophil depleted animals (Supplementary Fig. 
14). Accordingly, it was demonstrated that Il17a expression was significantly elevated in the 
lungs of neutrophil depleted mice, with the increase potentiated by HDM exposure (Fig. 4E). 
Expression analysis in T cells and ILC2s isolated from the lungs of HDM treated animals at 
this time point demonstrated that T cells were the primary source of IL-17 and that those 
derived from neutrophil depleted mice produced more of this cytokine (Supplementary 15A). 
This was supported by flow cytometry, with both CD4+ αβ T cells and γδ T cells derived from 
neutrophil depleted mice producing more IL-17 following 1 week of HDM administration 
(Supplementary 15B and C). IL-23 is a potent regulator of IL-17 expression and it has 
previously been demonstrated during homeostasis, that phagocytosis of transmigrated, 
apoptotic neutrophils by resident macrophages and dendritic cells suppresses their intrinsic IL-
23 production (38, 39). We thus questioned whether the failure of neutrophils to reach the lung 
in HDM challenged neutrophil-depleted mice would lead to an increase in IL-23 concentrations 
which would rationalize an ensuing increase in IL-17 and ultimately G-CSF. Consequently, 
Il23 expression was shown to be elevated in the lungs of neutrophil depleted animals 
administered HDM for 1 week (Fig. 4F). Flow cytometry analysis demonstrated that resident 
CD11c+ macrophages and moDCs were the primary sources of IL-23 in HDM treated mice, 
with increased numbers of IL-23+ moDCs present in neutrophil depleted animals 
(Supplementary 15D). Furthermore, both the CD11c+ macrophages and moDCs derived from 
neutrophil depleted HDM exposed mice produced more IL-23 on a per cell basis than those 
from HDM/control antibody treated animals (Supplementary 15E and F). Thus disruption of a 
peripheral feedback system, normally regulated by lung infiltrating, apoptotic neutrophils, 




Neutralization of G-CSF reduces the monocytosis and elevated TH2 cytokine levels observed 
in neutrophil depleted HDM exposed mice.  
We next sought to determine whether neutralization of G-CSF in our HDM model would 
abrogate the augmentation of bone marrow progenitors and tissue monocytes seen in neutrophil 
depleted animals. Mice exposed to HDM for 1 week were concomitantly treated with 2A3/1A8 
and anti-G-CSF neutralising antibody/control (Fig. 5A). Neutralization of G-CSF resulted in a 
significant reduction in neutrophils in HDM exposed animals (Fig. 5B), highlighting a 
prominent role for this mediator in defining neutrophilia in this model. Importantly, the 
increase in lung Ly6Clow and Ly6Chigh (Fig. 5C) monocytes observed in HDM treated mice 
depleted of neutrophils was completely negated following anti-G-CSF treatment. Furthermore, 
anti-G-CSF administration also reduced the percentage of bone marrow MDPs and CDPs (Fig. 
5D) in neutrophil depleted mice exposed to HDM for 1 week to a level observed in 2A3 treated 
animals. Thus, G-CSF, elevated as a consequence of neutrophil depletion, is driving the 
augmentation in bone marrow progenitors and ensuing increase in circulating and tissue 
monocytes. Reassuringly, the phenotype was largely recapitulated when IL-17 was neutralized 
in HDM exposed neutrophil-depleted mice, validating the importance of this cytokine in 
defining G-CSF levels (Supplementary Fig. 16A), and consequential changes in tissue 
neutrophils (Supplementary Fig. 16B) and monocytes (Supplementary Fig. 16C) and bone 
marrow progenitors (Supplementary Fig. 16D).  
Previously, we demonstrated that HDM-exposed neutrophil depleted mice exhibited a 
prominent increase in TH2 cytokine levels at 1 week of HDM exposure, which was attributable 
to augmented production on a per cell basis by ILC2s. Remarkably, the increase in BAL fluid 
concentrations of IL-4, IL-5 and IL-13 observed in neutrophil depleted mice after 1 week of 
HDM administration were significantly reduced upon anti-G-CSF administration (Fig. 5E). 
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Similarly, the amount of TH2 cytokines produced by ILC2s on a per cell basis, as exemplified 
by IL-13 and assessed by flow cytometry, were significantly reduced following anti-G-CSF 
administration to neutrophil depleted animals exposed to HDM (Fig. 5F) – a phenotype that 
was again conserved with anti-IL-17 treatment (Supplementary Fig. 16E).  
 
Recombinant G-CSF can augment ILC2 TH2 cytokine production. 
We next questioned whether the profound capacity of G-CSF to modulate ILC2 TH2 cytokine 
production and the expansion of bone marrow progenitor populations in HDM exposed animals 
was unique to mice depleted of neutrophils, or whether it could also operate comparably in 
fully immunocompetent animals. HDM exposed mice were therefore administered 
recombinant G-CSF for 1 week (Fig. 6A). Administration of recombinant G-CSF to HDM 
exposed mice further increased tissue neutrophils (Fig. 6B), but also augmented tissue 
monocytes (Fig. 6C) and bone marrow progenitors (Fig. 6D) – as seen following neutrophil 
depletion. Furthermore, HDM-driven increases in BALF IL-4, IL-5 and IL-13 (Fig. 6E) and 
ILC2 TH2 cytokine production (Fig. 6F) were also further accentuated by recombinant G-CSF 
administration. Thus G-CSF is a physiologically relevant regulator of ILC2 function and 
monocyte numbers.  
 
We next questioned whether G-CSF could directly act on ILC2s to potentiate cytokine 
production. Data mining of previous RNAseq data sets indicated that ILC2s express the G-CSF 
receptor, csf3r (40, 41), and this was confirmed in our HDM model with ILC2s isolated from 
the airways by FACS  expressing Csf3r (Fig. 7A). Csf3r expression was completely absent in 
T cells isolated from airways (Fig. 7A), rationalizing earlier observations that the primary 
source of IL-5 and IL-13 in neutrophil depleted animals was ILC2s and not CD4+ T cells. IL-
33 is a potent regulator of ILC2s, and a week-long model of intranasal recombinant IL-33 
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administration (Fig. 7B) induces substantial ILC2 numbers in the absence of an antigen-
specific TH2 cell response. Once again, ILC2s isolated from the airways of recombinant IL-33 
treated mice expressed Csf3r – which was again absent from T cells derived from these animals 
(Fig. 7C). When recombinant G-CSF was co-administered with recombinant IL-33 into the 
airways of mice (Fig. 7B) it augmented Il5 and Il13 expression within isolated airway ILC2s 
but not T cells, as adjudged by qPCR (Fig. 7D). Furthermore, co-administration of recombinant 
G-CSF with IL-33 increased BALF concentrations of IL5 and IL-13 (Fig. 7E).  
 
To validate that G-CSF was able to directly augment TH2 cytokine production from ILC2s, 
ILC2s were isolated from the airways of recombinant IL-33 treated mice (Supplementary Fig. 
17A) or from peripheral blood of healthy donors (Fig. 8A) and then stimulated with or without 
G-CSF. As observed with mouse ILC2s, human ILC2s exhibited robust expression of G-CSF 
receptor, CSF3R (Fig. 8B). Mouse and human ILC2s stimulated with G-CSF released 
significantly more IL-5 and IL-13 than medium treated control cells (Supplementary Fig. 17B 
and Fig. 8C, respectively), whereas levels IL-4, IL-17, IFN-γ and IL-12 were undetectable and 
levels of IL-6 and TNF-α were extremely low and comparable. Accordingly, IL5 and IL13 
message was significantly elevated in human ILC2s stimulated with G-CSF, as were levels of 
TH2 master transcriptional regulator GATA3 (Fig. 8D). Expression of IL4 and IL17 message 
was undetectable. Similarly, Il4, Il5 and Gata3 transcripts were dose-dependently augmented 
in mouse ILC2s stimulated with G-CSF (Supplementary Fig. 17C). Thus G-CSF is a previously 
unrecognised potentiator of TH2 cytokine production by ILC2s which, together with the 
augmented G-CSF-driven moDC antigen presentation, facilitates the greater type 2 






An over-exuberant or persistent neutrophilic response is implicated in the pathology of an array 
of inflammatory diseases, and neutrophils have consequently represented an attractive 
therapeutic target. However, therapeutic strategies that seek to ameliorate neutrophilic 
inflammation have failed to fully consider the potential regulatory roles fulfilled by these cells.  
In this study, we demonstrate that depletion of neutrophils in a HDM model of allergic airways 
disease led to perturbations of an IL-23 – IL-17 – G-CSF regulatory feedback pathway. The 
accumulated G-CSF subsequently promoted allergen sensitization and exacerbated type 2 
inflammation, epithelial remodelling and lung function. This was mediated by the capacity of 
G-CSF to promote TH2 cytokine production by airway ILC2s and to drive monocytosis and 
ensuing moDC-mediated antigen presentation (Supplementary Fig. 18).  
We demonstrate that G-CSF acts on Csf3r+ ILC2s to potentiate their production of IL-5 and 
IL-13 on a per cell basis. IL-4 levels were also elevated in vivo in a G-CSF-dependent manner, 
but was derived from Csf3r- CD4+ T cells - potentially attributable to the reported capacity of 
ILC2s to promote IL-4 production by CD4+ T cells (42–44). ILC2s are early effectors in type 
2 inflammation that sense and respond to cytokines and stress signals evoked from the proximal 
environment upon disruption of tissue homeostasis (45). It is, thus, rational that an innate 
mediator such as G-CSF can function to potentiate ILC2 function.  We also reveal the capacity 
to G-CSF to drive the expansion of bone marrow MDPs and CDPs and an ensuing monocytosis. 
Rationalizing this effect, G-CSF has previously been demonstrated to drive the expansion of 
granulocyte macrophage progenitor compartments (GMPs) within the bone marrow (46). 
GMPs lie developmentally upstream of MDPs and CDPs and may thus account for the 
accumulation of the latter in neutrophil depleted animals. Data mining of historic RNA-seq 
data sets (47) revealed that GMPs, MDPs and CDPs all express csf3r, supportive of the notion 
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that G-CSF is able to drive the proliferation of one or more of these progenitors. Whilst G-CSF 
is classically recognized as a potent regulator of granulopoiesis, G-CSF administration has been 
reported to stimulate monocyte production and release in neutropenic patients (48–50). In our 
allergen sensitized mice these expanded monocyte populations gave rise to augmented moDC 
numbers, which in keeping with previous literature (28, 30), transported antigen to draining 
MLNs and activated T cells - potentially further licensed by the elevated ILC2-derived IL-13 
(42). Thus, enhanced antigen presentation, in the context of elevated ILC2-derived type 2 
cytokines, in neutrophil depleted mice facilitated the increase in CD4+ TH2 cells after 3 weeks 
of allergen exposure. Similarly, the elevated levels of IL-4 would function to promote B cell 
responses and class switching that underlie the augmented levels of HDM-specific IgE and 
IgG1. 
 
Given the novel roles ascribed to G-CSF in this study, it is worth re-evaluating the broader 
implications of G-CSF in the context of asthma. Increased levels of G-CSF have been reported 
in the BALF of asthmatic patients relative to healthy controls (51), and in serum of patients 
with unstable asthma (52).  Pertinent to our current findings, G-CSF has been shown to increase 
concomitantly with IL-5 in unstable asthma (52), whilst  treatment of people with G-CSF 
augmented the number of circulating dendritic cells with the capacity to prime T cells to 
produce TH2 cytokines (53). Consequently, it is also appropriate to contextualize our findings 
with regards to the perceived role of neutrophils in asthma. The general consensus, based 
primarily on circumstantial clinical data, is that neutrophils are detrimental in the context of 
asthma and indicate a worse prognosis (8, 10–14). Based upon our current findings, it could be 
argued that neutrophils also represent a compensatory mechanism to indirectly restrain TH2 
inflammation in the context of allergic disease by negatively regulating the bioavailability of 
G-CSF. In keeping with this hypothesis, adoptive transfer of neutrophils has recently been 
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shown to attenuate TH2 responses in a mouse model of allergic airways disease (54). Our data 
in mice that neutrophils negatively regulate type 2 inflammation is supported by a previously 
reported case of a patient with cyclic neutropenia that suffered episodic acute asthma, whereby 
the cyclical depreciation in neutrophils concomitantly correlated with a substantial increase in 
eosinophils, serum IgE levels and asthma exacerbation (55).  Additionally, eosinophilia is a 
well-recognised feature of a number of primary immunodeficiency disorders associated with 
neutropenia (56). 
 
Our study demonstrates the complex regulatory feedback pathways that define neutrophil 
turnover, and the intrinsic challenges of targeting neutrophils as a therapeutic modality in the 
context of asthma. Any intervention that impacts on the ability of neutrophils to transmigrate 
into tissues at steady-state will likely modify G-CSF levels. Thus, mice deficient in CXCR2 
(39) or specific adhesion molecules (38) display increased baseline levels of G-CSF. 
Accordingly, therapeutic strategies employed to ameliorate neutrophilic inflammation in 
asthma may inadvertently augment G-CSF levels and potentiate TH2 inflammation. It is 
noteworthy, therefore, that CXCR2 antagonist AZD5069 reduced peripheral blood neutrophils 
in healthy volunteers but also caused a significant increase in serum G-CSF concentrations 
(57). Similarly, AZD5069 reduced lung, sputum and blood neutrophil numbers in patients with 
persistent asthma but again significantly increased G-CSF expression (57, 58). Furthermore, 
CXCR2 antagonist SCH526123 reduced sputum neutrophils in patients with severe asthma, 
but concomitantly increased the percentage sputum eosinophils (15).  It is feasible, therefore, 
that augmented G-CSF levels leading to increased TH2 inflammation could be a confounding 
factor that has contributed to the disappointing results of clinical trials with CXCR2 
antagonists. Alternative approaches which target neutrophilic inflammation in combination 
with reducing the compensatory increase in G-CSF could potentially be more clinically 
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beneficial. Alternatively, would we be better equipped with strategies that seek to promote 
neutrophil apoptosis in tissues (59–62), so as to reduce neutrophil numbers but simultaneously 
suppress the IL-23 – IL-17 – G-CSF axis?  More broadly, our study highlights the complexities 
of targeting neutrophils within the clinic and implies that broad-sword approaches to block 
neutrophils may be sub-optimal given neutrophils’ heterogeneity, pleiotropic functionality and 
regulatory capacity.  It would be prudent to gain a fuller understanding of pathways by which 
neutrophils instigate pathology in asthma so that these facets of their biology may be targeted 
more specifically. Our findings may also, of course, have implications outside the remit of 
asthma, whereby a multitude of animal studies have studied depletion or manipulation of 
neutrophil numbers in diverse inflammatory models, and numerous clinical trials have assessed 
therapies aimed at attenuating neutrophilic inflammation. Whilst we have demonstrated the 
consequence of G-CSF accumulation in the context of antigen sensitization and type 2 
inflammation of the airways, it will be intriguing to ascertain the implications in other 
experimental systems.  
In conclusion, we demonstrate that depletion of neutrophils in the context of a murine model 
of allergic airways disease, results in a dysregulated IL-23 – IL-17 – G-CSF feedback loop. 
Ensuing accumulation of G-CSF functioned to augment allergen sensitization by directly 
potentiating ILC2 TH2 cytokine production and acting on bone marrow progenitors to drive a 
monocytosis, which in turn resulted in augmented antigen presentation by moDCs. These 
studies are of basic biological significance in that they demonstrate previously unrecognized 
roles for G-CSF, and of translational significance in that they highlight the capacity of 
neutrophils to indirectly restrain allergic airway inflammation, potentially rationalizing the 





Materials and Methods: 
Study Design. 
The primary objective of this study was to define the importance of neutrophils in governing 
inflammation and pathology in allergic airway disease. In all experiments, appropriate control 
groups were utilised, and mice were housed under the same environmental conditions and were 
age-matched. Adult female mice were randomly placed in distinct experimental groups. 
Authors were blinded for cell counts and histology analysis. The number of mice in each group 
was determined by power calculations based on extensive previous experience with the model 
system and is defined in the respective figure legends. The number of independent replicates 
for each experiment is defined within the respective figure legends. No samples or animals 
were excluded from data analyses. 
Human isolated ILC2s were utilised to determine the direct effects of G-CSF on ILC2 
functionality. Blood was obtained from 3 male and 2 female donors. The number of donors 
was determined by previous experience with blood-derived ILC2 culturing methods. Authors 
were blinded from analysis of supernatant cytokine and mRNA expression analysis. All 




Eight to twelve-week-old female Balb/c mice were purchased from Envigo (Huntingdon, UK). 
All mice were randomly assigned to experimental groups. IL13-eGFP mice were kindly 
provided by A.N. McKenzie (MRC Laboratory of Molecular Biology, Cambridge) and 
subsequently bred in house (29). Mice were kept in specified pathogen-free conditions and 
provided autoclaved food, water and bedding. All mouse experiments were performed in 
accordance with the recommendations in the Guide for the Use of Laboratory Animals of 
22 
 
Imperial College London, with the ARRIVE (Animal Research: Reporting of In Vivo 
Experiments) guidelines. All animal procedures and care conformed strictly to the UK Home 
Office Guidelines under the Animals (Scientific Procedures) Act 1986, and the protocols were 
approved by the Home Office of Great Britain.  
 
Allergic airway disease murine model. 
Balb/c mice were administered 25 µg House Dust Mite (HDM) extract (10.17 µg/l DerP1, 9 
EU/ endotoxin content; Greer Laboratories) in 50 µl sterile PBS intranasally (i.n.) three times 
per week for up to 3 weeks. Control mice were administered 50 µl sterile PBS i.n. at analogous 
time points. All mice were culled 24 hours post the final dose of HDM or PBS. 
 
Recombinant IL-33 and G-CSF administration. 
Mice were intranasally administered 1 μg recombinant IL-33 protein (ThermoFisher Scientific) 
in 50μl PBS three times over a period of 1 week. In some experiments, mice were 
concomitantly intranasally administered 100 ng recombinant G-CSF (Peprotech, New Jersey, 
USA) in 50μl PBS (or PBS vehicle control) on a daily basis. When necessary, IL-33 was 
admixed with G-CSF for treatment of mice. Harvests were performed 24 hours post the final 
dose of IL-33. 
In other experiments, mice administered HDM (i.n.) for 1 week (as detailed above) were also 
treated daily with 2.5 μg of recombinant G-CSF i.p.  in 200μl PBS (or PBS vehicle control) 
and 100 ng G-CSF i.n. in 50μl PBS (or PBS vehicle control). Harvests were performed 24 
hours post the final dose of G-CSF/HDM. 
 
In vivo neutrophil depletion. 
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In order to deplete neutrophils, Balb/c mice received intraperitoneal (i.p.) administration of 100 
µg anti-Ly6G (clone 1A8, BioXCell) in 200 µl PBS. Control mice received 100 µg isotype 
control antibody (clone 2A3, BioXCell) in 200 µl PBS. During the allergic airways disease 
model, mice were administered the respective antibodies 24 hours prior to each HDM or PBS 
treatment.  
 
In vivo G-CSF neutralisation. 
Neutralisation of G-CSF was achieved by i.p. administration of 100 µg anti-mouse G-CSF 
antibody (R&D Systems). Respective control mice for G-CSF neutralisation received i.p. 
administration of 100 µg isotype control antibody (clone 2A3, R&D Systems). Where 
appropriate, the respective antibodies were admixed with anti-Ly6G antibody (clone 1A8, 
BioXCell) for neutrophil depleted mice or isotype control antibody (clone 2A3, BioXCell) for 
control mice. Antibodies were administered 24 hours prior to each HDM or PBS i.n. exposure. 
 
In-vivo IL-17 neutralisation. 
Neutralisation of IL-17 was achieved by i.p. administration of 20 µg anti-mouse IL-17A 
antibody (R&D Systems). Respective control mice for IL-17 neutralisation received i.p. 
administration of 20 µg isotype control antibody (clone 2A3, R&D Systems). Where 
appropriate, the respective antibodies were admixed with anti-Ly6G antibody (clone 1A8, 
BioXCell) for neutrophil depleted mice or isotype control antibody (clone 2A3, BioXCell) for 
control mice.  Antibodies were administered 24 hours prior to each HDM or PBS i.n. exposure. 
 
Administration of fluorescently-tagged ovalbumin. 
Ovalbumin (Invivogen) was tagged with Alexa Fluor 488 fluorophore utilising an Alexa Fluor 
488 Protein Labelling kit as per the manufacturer’s guidelines (ThermoFisher Scientific). Mice 
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were administered HDM i.n. for 1 week and upon the last HDM dose, mice received HDM 
mixed with 100 µg of Alexa Fluor-488 tagged Ovalbumin i.n. 
 
Lung function measurements. 
For studies where mice were administered HDM for 3 weeks, measurements of dynamic 
resistance, elastance and compliance were performed in anaesthetized and tracheotomized mice 
using a Flexi-vent system (SCIREQ) in response to increasing concentrations (0, 3, 10, 30, and 
100 mg/mL) of methacholine (Sigma-Aldrich), as described previously (63). 
 
Cell recovery and isolation. 
Mice were exsanguinated via cardiac puncture and 200 µl of blood was immediately lysed in 
ACK buffer (0.15 M ammonium chloride, 1 M potassium hydrogen carbonate and 0.01 mM 
EDTA, pH 7.2) for 5 minutes and subsequently centrifuged at 800 x g for 5 minutes before the 
cells were resuspended in 0.5 ml complete media (R10F; RPMI supplemented with 10% heat 
inactivated fetal bovine serum). Serum was isolated from excess clotted blood by centrifugation 
(8 min at 5,000 x g). Broncho-alveolar lavage (BAL) was performed by inflating the lungs 3 
times each with 0.4 ml of PBS via a tracheal cannula. The BAL fluid was then pooled and 
centrifuged at 800 x g for 5 minutes, and the BAL supernatant was collected and frozen at -80 
°C until required. The remaining cell pellet was re-suspended in 0.5 ml R10F. 
The accessory, middle and superior lobes of the right lung were snap frozen in liquid nitrogen 
and subsequently stored at -80 ºC until required. The left lobe was chopped finely and incubated 
at 37 ºC for 30 minutes in complete media containing 0.15 mg/mL Liberase (Sigma-Aldrich) 
and 25 μg/mL DNAse (Type 1, Sigma-Aldrich). The cells were recovered by disruption 
through a 70 µm sieve before being centrifuged at 800 x g for 5 minutes. Lysis of red blood 
cells in ACK buffer was performed for 3 minutes at room temperature before a final 
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centrifugation at 800 x g for 5 minutes and re-suspension of the remaining cell pellet in 2 ml 
R10F. 
Both femurs from each mouse were removed and freed of soft tissue attachments, and the 
extreme distal tip of each femur cut off. Both ends of the femurs were flushed with 1 ml of 
PBS containing 0.1% (wt/vol) sodium azide and 1% (wt/vol) BSA. The cells were carefully 
dispersed by filtration through a 70 µm sieve before being centrifuged at 800 x g for 5 minutes. 
Lysis of red blood cells in ACK buffer was performed for 3 minutes at room temperature before 
a final centrifugation at 800 x g for 5 minutes and re-suspension of the remaining cell pellet in 
2 ml R10F. 
The spleens of respective mice were disrupted through a 70 µm sieve and the suspension was 
centrifuged at 800 xg for 5 minutes. Red blood cell lysis was performed for 3 minutes utilising 
ACK buffer and the cells were centrifuged at 800 x g for 5 minutes before the final re-
suspension of the cell pellet in 2 ml R10F. 
Mediastinal lymph nodes were digested in 0.15 mg/mL Liberase (Sigma-Aldrich) for 30 
minutes. The cells were recovered by disruption through a 70 µm sieve before being 
centrifuged at 800 x g for 5 minutes. The cell pellet was subsequently resuspended in 2 ml 
R10F. 
FACS of leukocytes and stromal cells. 
Lungs of mice were inflated with 1.5 ml of 5 mg/ml Dispase II (Sigma-Aldrich) and then 
allowed to collapse naturally. Low-melting-point agarose (0.5 ml of 1% (wt/vol)) was then 
slowly injected into the lungs and was immediately solidified by packing of the lungs in ice. 
Lungs were then removed and incubated for 40 min in dispase solution. Lung tissue was 
subsequently transferred to DMEM containing Hepes (25 mM; ThermoFisher) and DNAse I 
(50 µg/ml; Sigma-Aldrich), and the digested tissue was 'teased away' from the upper airways 
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and incubated with gentle agitation for a further 30 minutes. Digested lung tissue was disrupted 
into single-cell suspensions by passage through a 70 µm sieve (BD Labware) before being 
centrifuged at 800 x g for 5 minutes. Lysis of red blood cells in ACK buffer was performed for 
3 minutes before a final centrifugation at 800 x g for 5 minutes and re-suspension of the 
remaining cell pellet in 2 ml R10F. Cell suspensions were stained with anti–mouse CD45-
PerCP, anti-mouse EpCAM-PE and anti–mouse CD31-APC as detailed below, and populations 
(endothelial cells: CD45- CD31+ EpCAM-; epithelial cells: CD45- CD31- EpCAM+; 
hematopoietic cells CD45+ CD31- EpCAM-) isolated by fluorescent-activated cell sorting 
(FACS) on a BD FACS LSR Aria III sorter. Isolated cells were centrifuged 800 x g for 5 
minutes and re-suspended in 350 μl RLT buffer (Qiagen) and stored at -80 ºC for real time 
PCR (see below). 
 
FACS of T cells and ILC2s. 
Single cell suspensions were obtained from lung tissue and BAL as described above in “Cell 
recovery and isolation”. For interrogation of airway T cells and ILC2s it was necessary to pool 
the BAL from 3 mice for each data point. Cell suspensions were stained with anti–mouse CD4-
FITC, anti-mouse CD45-PerCP, anti–mouse ICOS-PE-Cy7 and an internally made lineage 
(Lin) cocktail (consisting of TCRβ-APC, CD5-APC, CD19-APC, TCRγδ-APC, CD11b-APC, 
CD11c-APC, NKp46-APC, FCεR1-APC, GR-1-APC, F4/80-APC, TER-119-APC) as detailed 
in Supplementary Table 2, and populations (T cells: Lin+ CD45+ CD4+; ILC2s: Lin- CD45+ 
CD4- ICOS+KLRG1+) were isolated by FACS on a BD FACS LSR Aria III sorter. Isolated 
cells were centrifuged 800 x g for 5 minutes and re-suspended in 350 μl RLT buffer (Qiagen) 
and stored at -80 ºC for real time PCR (see below). 
 
Human ILC2 cultures. 
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Blood from healthy, non-allergic male (n = 3) and female (n=2) volunteers, with an age range 
of 24 - 40 years, was collected with written informed consent approved by the Brompton, 
Harefield and NHLI ethics committee. All experiments were carried out in accordance with the 
approved guidelines. Blood (50 ml) was collected from each donor via venepuncture and 
placed in 1 ml EDTA (0.5M, ThermoFisher Scientific). Whole blood ILC2s were enriched 
utilising the RosetteSepTM Human ILC2 Enrichment Kit (Stemcell Technologies, UK) as per 
manufacturer’s instructions. The enriched ILCs were then stained with anti-human lineage 
cocktail-FITC (ThermoFisher Scientific), anti-human CD45-PERCP (ThermoFisher 
Scientific) and anti-human CRTH2-BV421 (Biolegend) antibodies for 30 minutes before being 
sorted utilising a BD LSR Aria III cell sorter (BD Biosystems). The ILCs were identified as 
Lin- CD45+ CRTH2+. The isolated ILC2s were cultured in medium containing DMEM + 10 % 
FCS, IL-7 (5 ng/ml; PeproTech) and IL-33 (10 ng/ml; PeproTech) for 2 weeks. The cells were 
subsequently split and cultured in control medium or media supplemented with G-CSF (100 
ng/ml; PeproTech) for 72 hours. After stimulation, the cell supernatant was collected for 
protein analysis and the cells were lysed with 350 µl RLT buffer (Qiagen).  
 
Mouse ILC2 culture. 
Mice were administered 1 µg recombinant IL-33 (ThermoFisher Scientific) for 1 week as 
detailed above in “Recombinant IL-33 and G-CSF administration”. At 24 hours after the final 
IL-33 dose, lung tissue was extracted and single cell suspensions were obtained as described 
above in “Cell recovery and isolation”. ILC2s were sorted as described in “FACS of T cells 
and ILC2s”. Post sort, the isolated ILC2s were immediately plated in medium containing 
DMEM + 10% FCS, IL-7 (5 ng/ml; PeproTech) containing IL-33 (10 ng/ml; PeproTech) or 
lacking IL-33. Respective wells were subsequently supplemented with either media, 10 ng/ml 
G-CSF or 100 ng/ml G-CSF for 72 hours. After 72 hours, the supernatant was collected for the 
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measurement of IL-5 and IL-13 by ELISA and the cells were lysed in 350 µl RLT buffer 




Cells were stained with the LIVE/DEAD Fixable Near-IR-Dead Cell staining kit (Molecular 
Probes, Invitrogen) for 10 minutes in PBS before being blocked with anti-CD16/CD32 Fc 
receptor block (BD Pharmingen) for 20 minutes. Cells were then washed in PBS and stained 
for surface markers for 30 minutes at 4 ºC in PBS that contained 0.1% (wt/vol) sodium azide 
and 1% (wt/vol) BSA and were fixed with 2% (vol/vol) paraformaldehyde. All samples were 
acquired immediately on a BD LSR Fortessa cell analyser (BD Biosystems) and analysed using 
BD FACS DIVA (BD Biosystems). Cells were defined by markers, as described in 
Supplementary Table 2.  
For intracellular cytokine staining, single cell suspensions from lung tissue and BAL were 
stimulated with 40 ng/ml PMA (Sigma Aldrich) and 3 µg/ml ionomycin (MERCK Millipore) 
in complete medium supplemented with 10 µg/ml Brefeldin A (Sigma Aldrich) at 37 ºC, 0.5% 
CO2 for 3 hours. The cells were then stained for extracellular markers and fixed as stated above. 
Cells were subsequently permeabilized with saponin buffer (PBS with 0.05% (wt/vol) sodium 
azide, 1% (wt/vol) BSA and 1% (wt/vol) saponin (Sigma Aldrich)) containing anti-mouse IL-
13-PE, anti-mouse IL-5-BV421, anti-mouse IL-4-FITC, anti-mouse IL-17A-AlexaFluor 700 
and / or anti-mouse IL-23-PE-CY7. For Ki-67 staining, the cells were incubated with anti-
mouse Ki67-Alexa Fluor 488 antibodies.  Then, 30 minutes later, cells were washed once in 
saponin buffer and once in PBS containing 0.1% (wt/vol) sodium azide and 1% (wt/vol) BSA 
and data were acquired immediately on a BD LSR Fortessa cell analyser. 
Cytokine Analysis.  
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Murine superior and middle lung lobes were homogenized at a concentration of 50 mg/ml in 
PBS. Lung homogenates were centrifuged for 10 minutes (800 x g) and supernatant harvested 
for cytokine analysis. Lung homogenates, BAL fluid, serum and mouse ILC2 supernatants 
were assessed for concentrations of MMP-9, MPO, CCL2, CX3CL1, G-CSF (DuoSet; R&D 
Systems), IL-13 (ThermoFisher Scientific), IL-4 and IL-5 (BD Pharmingen), where relevant, 
by ELISA.  
Human ILC2 cell supernatants were assessed for cytokines using the LegendPlex Human Th 
helper cytokine kit. The preparation of samples was performed as per manufacturer’s 
instructions and recorded on a BD LSR FORTESSA flow cytometer (BD Biosystems).  
 
Measurement of Immunoglobulin concentrations. 
Total IgG1 and IgE (BD Biosciences, UK) were measured in diluted serum using standardized 
sandwich ELISAs according to the manufacturer’s protocol. Allergen specific IgE and IgG1 
were measured in diluted serum as previously described (64).  
 
Measurement of airway mucin concentrations. 
BALF MUC5AC protein was determined using a previously described protocol (65). In brief, 
BAL fluid was placed on a 96 well plate (Corning, U.K.) and allowed to evaporate overnight 
at 37 ºC. The plate was subsequently washed and blocked with 2% BSA for 2 hours. Protein 
Muc5ac was measured using a biotinylated anti-Muc5ac detection antibody (400 ng/ml; 
ThermoFisher Scientific).  
 
Quantitative RT-PCR. 
For whole lung, tissue was homogenised in RLT buffer (Qiagen) and total RNA was extracted 
using RNeasy Plus Mini Kit (Qiagen).  Reverse transcription was subsequently performed 
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using the High-Capacity cDNA Reverse Transcription Kit (ThermoFisher). For suspensions of 
isolated cell populations (in RLT buffer (Qiagen)), total RNA was extracted using RNeasy Plus 
Micro Kit (Qiagen) and reverse transcription was performed using GoScript™ Reverse 
Transcriptase kit (Promega). Taqman gene expression assays (ThermoFisher Scientific) were 
used to assess relative expression of murine Csf3, Csf3r, Cxcl1, Il4, Il5, Il13, Il17, Il23, Gata3 
and Muc5ac mRNA expression and normalised to Gapdh. Similarly, relative expression of 
human IL5, IL13 and GATA3 expression was normalised to GAPDH. Quantitative RT-PCR 
was performed on a Viaa7 Real-Time PCR System (ThermoFisher Scientific). Data were 
obtained from two technical replicates and expressed as fold change in ''CT from respective 
control groups or relative expression of gene (calculated as 1000*'CT2). 
 
Precision cut lung slicing. 
Control and neutrophil depleted mice were administered HDM i.n. for 1 week. 24 hours post 
the final HDM dose, anti-mouse CD31-Alexa Fluor 647 (ThermoFisher Scientific), anti-mouse 
CD115-PE (Biolegend) and anti-mouse Ly6G-Alexa Fluor-488 (Biolegend) antibodies (at a 
concentration of 50 µg/ml) were injected i.v. to stain blood cells approximately 5 minutes 
before harvesting. Anti-mouse CD115-PE (Biolegend), anti-mouse Ly6G- Alexa Fluor 488 
(Biolegend) and anti-mouse CD11c-BV421 (Biolegend) antibodies (at a concentration of 50 
µg/ml) was also administered i.n. to stain cells within the airways. Mice were harvested and 
the tracheas were exposed, and the lungs were inflated with 1 ml of 2 % low melting point 
agarose (ThermoFisher Scientific). Once the agarose was solidified, the right lung lobe was 
isolated and sliced to 300 μl thickness using a BIO-RAD H1200 vibratome (BIO-RAD, 
France). The lung slices were immediately washed twice in R10F. To ensure staining of tissue 
resident cells, the lung slices were incubated with anti-mouse CD115-PE (Biolegend), anti- 
mouse Ly6G-Alexa Fluor-488 (Biolegend), anti-mouse CD115-PE (Biolegend), anti-mouse 
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Ly6G- Alexa Fluor 488 (Biolegend) and anti-mouse CD11c-BV421 (Biolegend) antibodies (at 
a concentration of 50 µg/ml) for 30 minutes at room temperature.  The fully stained lung slices 
were washed three times with R10F before being mounted onto an imaging µ-plate (IBIDI). 
Images were obtained with an inverted SP5 confocal microscope using a 20x objective (Leica, 
UK). The images were subsequently analysed and prepared using Imaris software version 8.1 
(Bitplane, Oxford Instruments, UK).   
 
Lung sectioning for H&E staining. 
Following 3 weeks of HDM / PBS exposure, histology assessment was performed as previously 
described (63). In brief, the inferior lobe of the right lung was fixed with 10% neutral buffered 
formalin for 24 hours. The lungs were then paraffin wax embedded and cut to 4 µm thickness. 




Statistical significance was calculated with a nonparametric Mann-Whitney test (two-sided) 
and Prism software (GraphPad Software, Inc.). Statistical significance for Human ILC2 
experiments was calculated using a paired t-test. Statistical significance for Mouse ILC2 
experiments was calculated using an ANOVA test with Bonferroni correction. Results are 
depicted as mean ± SEM unless stated otherwise. Statistical significance for correlations was 
calculated using a Spearman Rank test with p-values and r-values noted on the respective 
graphs. All P values of <0.05 (*), <0.01 (**), <0.001 (***) and <0.0001 (****) were considered 






Supplementary Fig. 1: Intranasal administration of HDM induces neutrophilic inflammation in 
the lungs and airways of mice. 
Supplementary Fig. 2: Intranasal administration of HDM induces an increase in neutrophil 
proteases in the lungs and airways of mice. 
Supplementary Fig. 3: Intraperitoneal administration of anti-Ly6G antibody, 1A8, systemically 
depletes neutrophils in HDM treated mice. 
Supplementary Fig. 4: Intraperitoneal administration of anti-Ly6G antibody, 1A8, specifically 
depletes neutrophils. 
Supplementary Fig. 5: Neutrophil depleted mice display augmented type 2 inflammation, 
epithelial remodelling and airway resistance after 3 weeks of HDM exposure. 
Supplementary Fig. 6: Neutrophil depleted mice display comparable airway 
hyperresponsiveness after 3 weeks of HDM exposure. 
Supplementary Fig. 7: Augmented TH2 cytokine levels in neutrophil depleted mice 
administered HDM for 1 week. 
Supplementary Fig. 8: ILC2s are the predominant source of IL-13 after 1 week of HDM 
administration. 
Supplementary Fig. 9: Gating strategy for isolation of ILC2s and CD4+ T cells by fluorescence 
activated cell sorting. 
Supplementary Fig. 10: Augmented IL-5 and IL-13 levels in lungs of neutrophil depleted mice 
administered HDM for 1 week are primarily derived from ILC2s. 
Supplementary Fig. 11: ILC2s from neutrophil depleted mice administered HDM for 1 week 
produce more IL-5 and IL-13 on a per cell basis. 
Supplementary Fig. 12: HDM exposed, neutrophil depleted mice exhibit augmented dendritic 
cell numbers and antigen presentation. 
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Supplementary Fig. 13: Lung concentrations of classical monocyte chemokines and flow 
cytometry gating strategy to identify monocyte dendritic cell progenitors (MDPs) and common 
dendritic cell progenitors (CDPs).  
Supplementary Fig. 14: G-CSF is elevated in the serum of neutrophil depleted mice 
administered HDM. 
Supplementary Fig. 15: Neutrophil depleted mice administered HDM produce elevated levels 
of IL-17 and IL-23. 
Supplementary Fig. 16: Neutralization of IL-17 reverts the effects of neutrophil depletion in 
HDM administered mice. 
Supplementary Fig. 17: G-CSF directly augments TH2 cytokine production from mouse ILC2s.  
Supplementary Fig. 18: Neutrophil depletion alters the IL-23 – IL-17 – G-CSF regulatory 
feedback pathway to exacerbate TH2 cytokine production and allergen sensitisation. 
 
Supplementary Table 1: Raw data file. 











1. M. K. Richards, F. Liu, H. Iwasaki, K. Akashi, D. C. Link, Pivotal role of granulocyte 
colony-stimulating factor in the development of progenitors in the common myeloid pathway., 
Blood 102, 3562–8 (2003). 
2. B. I. Lord, M. H. Bronchud, S. Owens, J. Chang, A. Howell, L. Souza, T. M. Dexter, The 
kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating 
factor in vivo., Proc. Natl. Acad. Sci. U. S. A. 86, 9499–503 (1989). 
3. G. J. Lieschke, D. Grail, G. Hodgson, D. Metcalf, E. Stanley, C. Cheers, K. J. Fowler, S. 
Basu, Y. F. Zhan, A. R. Dunn, Mice lacking granulocyte colony-stimulating factor have 
chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired 
neutrophil mobilization., Blood 84, 1737–46 (1994). 
4. F. Liu, H. Y. Wu, R. Wesselschmidt, T. Kornaga, D. C. Link, Impaired production and 
increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient 
mice., Immunity 5, 491–501 (1996). 
5. C. Summers, S. M. Rankin, A. M. Condliffe, N. Singh, A. M. Peters, E. R. Chilvers, 
Neutrophil kinetics in health and disease., Trends Immunol. 31, 318–24 (2010). 
6. A. M. Wengner, S. C. Pitchford, R. C. Furze, S. M. Rankin, The coordinated action of G-
CSF and ELR + CXC chemokines in neutrophil mobilization during acute inflammation., 
Blood 111, 42–9 (2008). 
7. A. Mantovani, M. a Cassatella, C. Costantini, S. Jaillon, Neutrophils in the activation and 
regulation of innate and adaptive immunity., Nat. Rev. Immunol. 11, 519–31 (2011). 
8. R. J. Snelgrove, D. F. Patel, T. Patel, C. M. Lloyd, The enigmatic role of the neutrophil in 
35 
 
asthma: Friend, foe or indifferent?, Clin. Exp. Allergy 48, 1275–1285 (2018). 
9. J. V Fahy, K. W. Kim, J. Liu, H. A. Boushey, Prominent neutrophilic inflammation in 
sputum from subjects with asthma exacerbation, J Allergy Clin Immunol 95, 843–852 (1995). 
10. M. Gauthier, A. Ray, S. E. Wenzel, Evolving concepts of asthma, Am. J. Respir. Crit. Care 
Med. 192, 660–668 (2015). 
11. R. Louis, L. C. Lau, A. O. Bron, A. C. Roldaan, M. Radermecker, R. Djukanović, The 
relationship between airways inflammation and asthma severity., Am. J. Respir. Crit. Care 
Med. 161, 9–16 (2000). 
12. W. C. Moore, A. T. Hastie, X. Li, H. Li, W. W. Busse, N. N. Jarjour, S. E. Wenzel, S. P. 
Peters, D. A. Meyers, E. R. Bleecker,  and B. I. S. A. R. P. National Heart, Lung, Sputum 
neutrophil counts are associated with more severe asthma phenotypes using cluster analysis., 
J. Allergy Clin. Immunol. 133, 1557–63.e5 (2014). 
13. S. E. Wenzel, S. J. Szefler, D. Y. Leung, S. I. Sloan, M. D. Rex, R. J. Martin, Bronchoscopic 
evaluation of severe asthma. Persistent inflammation associated with high dose 
glucocorticoids, Am J Respir Crit Care Med 156, 737–743 (1997). 
14. S. E. Wenzel, Asthma phenotypes: the evolution from clinical to molecular approaches, 
Nat Med 18, 716–725 (2012). 
15. P. Nair, M. Gaga, E. Zervas, K. Alagha, F. E. Hargreave, P. M. O’Byrne, P. Stryszak, L. 
Gann, J. Sadeh, P. Chanez, Study Investigators, Safety and efficacy of a CXCR2 antagonist in 
patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical 
trial., Clin. Exp. Allergy 42, 1097–103 (2012). 
16. P. M. O’Byrne, H. Metev, M. Puu, K. Richter, C. Keen, M. Uddin, B. Larsson, M. Cullberg, 
36 
 
P. Nair, Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled 
persistent asthma: a randomised, double-blind, placebo-controlled trial., Lancet. Respir. Med. 
4, 797–806 (2016). 
17. D. J. Evans, P. J. Barnes, S. M. Spaethe, E. L. van Alstyne, M. I. Mitchell, B. J. O’Connor, 
Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in 
asthma., Thorax 51, 1178–84 (1996). 
18. Y. S. Wasfi, C. Villarán, C. L. B. de Tilleghem, S. S. Smugar, W. D. Hanley, T. F. Reiss, 
B. A. Knorr, The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic 
asthma., Respir. Med. 106, 34–46 (2012). 
19. R. Chaudhuri, V. Norris, K. Kelly, C.-Q. Zhu, C. Ambery, J. Lafferty, E. Cameron, N. C. 
Thomson, Effects of a FLAP inhibitor, GSK2190915, in asthmatics with high sputum 
neutrophils., Pulm. Pharmacol. Ther. 27, 62–9 (2014). 
20. W. Barchuk, J. Lambert, R. Fuhr, J. Z. Jiang, K. Bertelsen, A. Fourie, X. Liu, P. E. Silkoff, 
E. S. Barnathan, R. Thurmond, Effects of JNJ-40929837, a leukotriene A4 hydrolase inhibitor, 
in a bronchial allergen challenge model of asthma., Pulm. Pharmacol. Ther. 29, 15–23 (2014). 
21. W. W. Busse, S. Holgate, E. Kerwin, Y. Chon, J. Feng, J. Lin, S.-L. Lin, Randomized, 
double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor 
monoclonal antibody, in moderate to severe asthma., Am. J. Respir. Crit. Care Med. 188, 1294–
302 (2013). 
22. L. G. Gregory, B. Causton, J. R. Murdoch, S. A. Mathie, V. O’Donnell, C. P. Thomas, F. 
M. Priest, D. J. Quint, C. M. Lloyd, Inhaled house dust mite induces pulmonary T helper 2 
cytokine production, Clin Exp Allergy 39, 1597–1610 (2009). 
37 
 
23. J. M. Daley, A. a Thomay, M. D. Connolly, J. S. Reichner, J. E. Albina, Use of Ly6G-
specific monoclonal antibody to deplete neutrophils in mice., J. Leukoc. Biol. 83, 64–70 (2008). 
24. I. R. Dunay, A. Fuchs, L. D. Sibley, Inflammatory monocytes but not neutrophils are 
necessary to control infection with Toxoplasma gondii in mice., Infect. Immun. 78, 1564–70 
(2010). 
25. J.-X. Wang, A. M. Bair, S. L. King, R. Shnayder, Y.-F. Huang, C.-C. Shieh, R. J. Soberman, 
R. C. Fuhlbrigge, P. A. Nigrovic, Ly6G ligation blocks recruitment of neutrophils via a β2-
integrin-dependent mechanism., Blood 120, 1489–98 (2012). 
26. B. Becher, A. Schlitzer, J. Chen, F. Mair, H. R. Sumatoh, K. W. W. Teng, D. Low, C. 
Ruedl, P. Riccardi-Castagnoli, M. Poidinger, M. Greter, F. Ginhoux, E. W. Newell, High-
dimensional analysis of the murine myeloid cell system., Nat. Immunol. 15, 1181–9 (2014). 
27. A. Hasenberg, M. Hasenberg, L. Männ, F. Neumann, L. Borkenstein, M. Stecher, A. Kraus, 
D. R. Engel, A. Klingberg, P. Seddigh, Z. Abdullah, S. Klebow, S. Engelmann, A. Reinhold, 
S. Brandau, M. Seeling, A. Waisman, B. Schraven, J. R. Göthert, F. Nimmerjahn, M. Gunzer, 
Catchup: a mouse model for imaging-based tracking and modulation of neutrophil 
granulocytes., Nat. Methods 12, 445–52 (2015). 
28. B. N. Lambrecht, H. Hammad, The immunology of asthma., Nat. Immunol. 16, 45–56 
(2015). 
29. D. R. Neill, S. H. Wong, A. Bellosi, R. J. Flynn, M. Daly, T. K. A. Langford, C. Bucks, C. 
M. Kane, P. G. Fallon, R. Pannell, H. E. Jolin, A. N. J. McKenzie, Nuocytes represent a new 
innate effector leukocyte that mediates type-2 immunity, Nature 464, 1367–1370 (2010). 
30. M. Plantinga, M. Guilliams, M. Vanheerswynghels, K. Deswarte, F. Branco-Madeira, W. 
38 
 
Toussaint, L. Vanhoutte, K. Neyt, N. Killeen, B. Malissen, H. Hammad, B. N. Lambrecht, 
Conventional and Monocyte-Derived CD11b+ Dendritic Cells Initiate and Maintain T Helper 
2 Cell-Mediated Immunity to House Dust Mite Allergen, Immunity 38, 322–335 (2013). 
31. D. K. Fogg, C. Sibon, C. Miled, S. Jung, P. Aucouturier, D. R. Littman, A. Cumano, F. 
Geissmann, A Clonogenic Bone Marrow Progenitor Specific for Macrophages and Dendritic 
Cells, Science (80-. ). 311, 83–87 (2006). 
32. A. Schlitzer, V. Sivakamasundari, J. Chen, H. R. Bin Sumatoh, J. Schreuder, J. Lum, B. 
Malleret, S. Zhang, A. Larbi, F. Zolezzi, L. Renia, M. Poidinger, S. Naik, E. W. Newell, P. 
Robson, F. Ginhoux, Identification of cDC1- and cDC2-committed DC progenitors reveals 
early lineage priming at the common DC progenitor stage in the bone marrow, Nat. Immunol. 
16, 718–728 (2015). 
33. M. A. Meyer, J. M. Baer, B. L. Knolhoff, T. M. Nywening, R. Z. Panni, X. Su, K. N. 
Weilbaecher, W. G. Hawkins, C. Ma, R. C. Fields, D. C. Linehan, G. A. Challen, R. Faccio, 
R. L. Aft, D. G. DeNardo, Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell 
development to overcome immune surveillance., Nat. Commun. 9, 1250 (2018). 
34. S. Sivakumaran, S. Henderson, S. Ward, P. S. E. Sousa, T. Manzo, L. Zhang, T. Conlan, 
T. K. Means, M. D’Aveni, O. Hermine, M.-T. Rubio, R. Chakraverty, C. L. Bennett, Depletion 
of CD11c+ cells in the CD11c.DTR model drives expansion of unique CD64+ Ly6C+ 
monocytes that are poised to release TNF-α., Eur. J. Immunol. 46, 192–203 (2016). 
35. E. Smith, M. A. Stark, A. Zarbock, T. L. Burcin, A. C. Bruce, D. Vaswani, P. Foley, K. 
Ley, IL-17A inhibits the expansion of IL-17A-producing T cells in mice through “short-loop” 
inhibition via IL-17 receptor., J. Immunol. 181, 1357–64 (2008). 
36. C. E. Jones, K. Chan, Interleukin-17 stimulates the expression of interleukin-8, growth-
39 
 
related oncogene-alpha, and granulocyte-colony-stimulating factor by human airway epithelial 
cells., Am. J. Respir. Cell Mol. Biol. 26, 748–53 (2002). 
37. P. Schwarzenberger, W. Huang, P. Ye, P. Oliver, M. Manuel, Z. Zhang, G. Bagby, S. 
Nelson, J. K. Kolls, Requirement of endogenous stem cell factor and granulocyte-colony-
stimulating factor for IL-17-mediated granulopoiesis., J. Immunol. 164, 4783–9 (2000). 
38. J. Mei, Y. Liu, N. Dai, C. Hoffmann, K. M. Hudock, P. Zhang, S. H. Guttentag, J. K. Kolls, 
P. M. Oliver, F. D. Bushman, G. S. Worthen, Cxcr2 and Cxcl5 regulate the IL-17/G-CSF axis 
and neutrophil homeostasis in mice., J. Clin. Invest. 122, 974–86 (2012). 
39. M. A. Stark, Y. Huo, T. L. Burcin, M. A. Morris, T. S. Olson, K. Ley, Phagocytosis of 
Apoptotic Neutrophils Regulates Granulopoiesis via IL-23 and IL-17, Immunity 22, 285–294 
(2005). 
40. M. L. Robinette, A. Fuchs, V. S. Cortez, J. S. Lee, Y. Wang, S. K. Durum, S. Gilfillan, M. 
Colonna, Immunological Genome Consortium, Transcriptional programs define molecular 
characteristics of innate lymphoid cell classes and subsets., Nat. Immunol. 16, 306–17 (2015). 
41. A. Wallrapp, S. J. Riesenfeld, P. R. Burkett, R.-E. E. Abdulnour, J. Nyman, D. Dionne, M. 
Hofree, M. S. Cuoco, C. Rodman, D. Farouq, B. J. Haas, T. L. Tickle, J. J. Trombetta, P. Baral, 
C. S. N. Klose, T. Mahlakõiv, D. Artis, O. Rozenblatt-Rosen, I. M. Chiu, B. D. Levy, M. S. 
Kowalczyk, A. Regev, V. K. Kuchroo, The neuropeptide NMU amplifies ILC2-driven allergic 
lung inflammation., Nature 549, 351–356 (2017). 
42. T. Y. F. Halim, Y. Y. Hwang, S. T. Scanlon, H. Zaghouani, N. Garbi, P. G. Fallon, A. N. 
J. McKenzie, Group 2 innate lymphoid cells license dendritic cells to potentiate memory TH2 
cell responses., Nat. Immunol. 17, 57–64 (2016). 
40 
 
43. C. J. Oliphant, Y. Y. Hwang, J. A. Walker, M. Salimi, S. H. Wong, J. M. Brewer, A. 
Englezakis, J. L. Barlow, E. Hams, S. T. Scanlon, G. S. Ogg, P. G. Fallon, A. N. J. McKenzie, 
MHCII-Mediated Dialog between Group 2 Innate Lymphoid Cells and CD4+ T Cells 
Potentiates Type 2 Immunity and Promotes Parasitic Helminth Expulsion, Immunity 41, 283–
295 (2014). 
44. L. Y. Drake, H. Kita, Group 2 innate lymphoid cells in the lung., Adv. Immunol. 124, 1–16 
(2014). 
45. C. M. Lloyd, R. J. Snelgrove, Type 2 immunity: Expanding our view., Sci. Immunol. 3, 
eaat1604 (2018). 
46. S. Bugl, S. Wirths, M. P. Radsak, H. Schild, P. Stein, M. C. André, M. R. Müller, E. 
Malenke, T. Wiesner, M. Märklin, J.-S. Frick, R. Handgretinger, H.-G. Rammensee, L. Kanz, 
H.-G. Kopp, Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling., 
Blood 121, 723–33 (2013). 
47. A. Yáñez, S. G. Coetzee, A. Olsson, D. E. Muench, B. P. Berman, D. J. Hazelett, N. 
Salomonis, H. L. Grimes, H. S. Goodridge, Granulocyte-Monocyte Progenitors and Monocyte-
Dendritic Cell Progenitors Independently Produce Functionally Distinct Monocytes, Immunity 
47, 890-902.e4 (2017). 
48. H. M. Mehta, M. Malandra, S. J. Corey, G-CSF and GM-CSF in Neutropenia., J. Immunol. 
195, 1341–9 (2015). 
49. K. E. Lawlor, I. K. Campbell, D. Metcalf, K. O’Donnell, A. van Nieuwenhuijze, A. W. 
Roberts, I. P. Wicks, Critical role for granulocyte colony-stimulating factor in inflammatory 
arthritis, Proc. Natl. Acad. Sci. 101, 11398–11403 (2004). 
41 
 
50. A. Fattorossi, A. Battaglia, L. Pierelli, P. Malinconico, L. Andreocci, A. Perillo, G. 
Ferrandina, O. Martelli, A. Rughetti, M. Nuti, E. Cortesi, G. Scambia, Effects of granulocyte-
colony-stimulating factor and granulocyte/macrophage-colony-stimulating factor 
administration on T cell proliferation and phagocyte cell-surface molecules during 
hematopoietic reconstitution after autologous peripheral blood progenitor cell transplantation., 
Cancer Immunol. Immunother. 49, 641–8 (2001). 
51. K. Hosoki, S. Ying, C. Corrigan, H. Qi, A. Kurosky, K. Jennings, Q. Sun, I. Boldogh, S. 
Sur, Analysis of a Panel of 48 Cytokines in BAL Fluids Specifically Identifies IL-8 Levels as 
the Only Cytokine that Distinguishes Controlled Asthma from Uncontrolled Asthma, and 
Correlates Inversely with FEV1., PLoS One 10, e0126035 (2015). 
52. M. Kato, Y. Yamada, K. Maruyama, Y. Hayashi, Serum eosinophil cationic protein and 27 
cytokines/chemokines in acute exacerbation of childhood asthma., Int. Arch. Allergy Immunol. 
152 Suppl, 62–6 (2010). 
53. M. Arpinati, C. L. Green, S. Heimfeld, J. E. Heuser, C. Anasetti, Granulocyte-colony 
stimulating factor mobilizes T helper 2-inducing dendritic cells., Blood 95, 2484–90 (2000). 
54. N. Nowroozilarki, H. H. Öz, C. Schroth, A. Hector, B. Nürnberg, D. Hartl, S. Kolahian, 
Anti-inflammatory role of CD11b+Ly6G+ neutrophilic cells in allergic airway inflammation 
in mice., Immunol. Lett. 204, 67–74 (2018). 
55. A. N. Salazar Cabrera, R. Berrón Pérez, J. A. Ortega Martell, E. Onuma Takane, Asthma 
and cyclic neutropenia., Allergol. Immunopathol. (Madr). 24, 25–8 (1996). 
56. B. Navabi, J. E. M. Upton, Primary immunodeficiencies associated with eosinophilia., 
Allergy Asthma. Clin. Immunol. 12, 27 (2016). 
42 
 
57. S. Jurcevic, C. Humfrey, M. Uddin, S. Warrington, B. Larsson, C. Keen, The effect of a 
selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune 
functions., Br. J. Clin. Pharmacol. 80, 1324–36 (2015). 
58. H. Watz, M. Uddin, F. Pedersen, A. Kirsten, T. Goldmann, F. Stellmacher, E. Groth, B. 
Larsson, G. Böttcher, A. Malmgren, M. Kraan, K. F. Rabe, Effects of the CXCR2 antagonist 
AZD5069 on lung neutrophil recruitment in asthma., Pulm. Pharmacol. Ther. 45, 121–123 
(2017). 
59. S. Fox, A. E. Leitch, R. Duffin, C. Haslett, A. G. Rossi, Neutrophil apoptosis: relevance to 
the innate immune response and inflammatory disease., J. Innate Immun. 2, 216–27 (2010). 
60. L. J. Hoodless, C. D. Lucas, R. Duffin, M. A. Denvir, C. Haslett, C. S. Tucker, A. G. Rossi, 
Genetic and pharmacological inhibition of CDK9 drives neutrophil apoptosis to resolve 
inflammation in zebrafish in vivo., Sci. Rep. 5, 36980 (2016). 
61. C. D. Lucas, K. C. Allen, D. A. Dorward, L. J. Hoodless, L. A. Melrose, J. A. Marwick, C. 
S. Tucker, C. Haslett, R. Duffin, A. G. Rossi, Flavones induce neutrophil apoptosis by down-
regulation of Mcl-1 via a proteasomal-dependent pathway., FASEB J. 27, 1084–94 (2013). 
62. L. J. Hoodless, C. D. Lucas, R. Duffin, M. A. Denvir, C. Haslett, C. S. Tucker, A. G. Rossi, 
Genetic and pharmacological inhibition of CDK9 drives neutrophil apoptosis to resolve 
inflammation in zebrafish in vivo, Sci. Rep. 6, 36980 (2016). 
63. D. F. Patel, T. Peiró, A. Shoemark, S. Akthar, S. A. Walker, A. M. Grabiec, P. L. Jackson, 
T. Hussell, A. Gaggar, X. Xu, J. L. Trevor, J. Li, C. Steele, G. Tavernier, J. E. Blalock, R. M. 
Niven, L. G. Gregory, A. Simpson, C. M. Lloyd, R. J. Snelgrove, An extracellular matrix 




64. S. Löser, L. G. Gregory, Y. Zhang, K. Schaefer, S. A. Walker, J. Buckley, L. Denney, C. 
H. Dean, W. O. C. Cookson, M. F. Moffatt, C. M. Lloyd, Pulmonary ORMDL3 is critical for 
induction of Alternaria-induced allergic airways disease., J. Allergy Clin. Immunol. 139, 1496-
1507.e3 (2017). 
65. A. Singanayagam, N. Glanville, J. L. Girkin, Y. M. Ching, A. Marcellini, J. D. Porter, M. 
Toussaint, R. P. Walton, L. J. Finney, J. Aniscenko, J. Zhu, M.-B. Trujillo-Torralbo, M. A. 
Calderazzo, C. Grainge, S.-L. Loo, P. C. Veerati, P. S. Pathinayake, K. S. Nichol, A. T. Reid, 
P. L. James, R. Solari, P. A. B. Wark, D. A. Knight, M. F. Moffatt, W. O. Cookson, M. R. 
Edwards, P. Mallia, N. W. Bartlett, S. L. Johnston, Corticosteroid suppression of antiviral 
immunity increases bacterial loads and mucus production in COPD exacerbations., Nat. 













Acknowledgements: We thank Lorraine Lawrence for histological sectioning and staining.  
Funding: RJS is a Wellcome Trust Senior Research Fellow in Basic Biomedical Sciences 
(209458/Z/17/Z). CML is a Wellcome Trust Senior Fellow in Basic Biomedical Sciences 
(107059/Z/15/Z). TP is supported by a Marie Curie Intra European Fellowship within the 7th 
European Community Framework Programme (FP7-PEOPLE-2013-IEF No627374). AS is 
supported by a pump priming grant from the British Lung Foundation (PPRG15-9) and a 
research grant from the British Medical Association (HC Roscoe 2015 grant). Aspects of the 
work were funded by an award from the Rosetrees Trust (M612) to RJS, LG and CML. LMC. 
is funded by core support from Cancer Research UK (A23983 and A17196), the MRC 
(MR/M01245X/1), and the National Heart & Lung Institute Foundation. 
 
Author Contributions: DFP and RJS designed and interpreted the experiments, performed 
statistical analysis and prepared the manuscript. DFP, with the assistance of TP, NB, JV, SA, 
FP, CJP, KS, AS, SAW, LGG and RJS performed the majority of the experiments. LMC and 
CML provided key reagents and contributed discussions throughout the work.  
 









Figure 1: Neutrophil depleted mice display augmented type 2 inflammation after 3 weeks of 
HDM exposure. 
(A) Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for up to 
3 weeks, and at 24 hours prior to each HDM/PBS administration mice were dosed with either 
100 µg of neutrophil depleting antibody, 1A8, or isotype control antibody, 2A3 
intraperitoneally (i.p.). At 24 hours, 1 week and 3 week time points (in each instance 24 hours 
post final HDM/PBS exposure), lung tissue and BALF was collected (Ŧ). Total numbers of 
neutrophils in the lungs (B) and airways (C) were determined by flow cytometry. (D) Total cell 
numbers in the lung were assessed after 3 weeks of HDM exposure by trypan blue exclusion. 
(E) Representative H&E stained lung sections from mice exposed to PBS or HDM for 3 weeks 
and treated with 2A3 or 1A8. (F) The number of eosinophils in the lung were quantified by 
flow cytometry at 3 weeks. The number of CD4+ T cells expressing T1ST2 (G) or IL-13 (H) 
in the lung were assessed by flow cytometry after 3 weeks of PBS/HDM exposure. (I) After 3 
weeks of HDM/PBS exposure, concentrations of HDM-specific IgE and IgG1 in the serum 
were determined by ELISA. Figures present combined data from 2 independent experiments 
with 4-6 mice per group in each experiment. Results depicted as mean ± SEM. *P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001 using Mann–Whitney statistical test.  
 
Figure 2: Augmented TH2 cytokine production by ILC2s in neutrophil depleted mice 
administered HDM for 1 week.  
(A) Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 1 
week and at 24 hours prior to each HDM treatment, mice were dosed with either 100 µg of 
neutrophil depleting antibody, 1A8, or isotype control antibody, 2A3 intraperitoneally (i.p.).  
At 24 hours post the final HDM administration BALF was collected (Ŧ). (B) Concentrations 
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of IL-4, IL-5 and IL-13 protein were assessed in and BALF by ELISA. In some experiments, 
CD4+ T cells and ILC2s (pooled from 3 mice per data point) were isolated from the airways by 
FACS, at 24 hours post final HDM exposure, for subsequent mRNA gene expression analysis. 
(C) Relative expression of Il-4, Il-5, Il-13 and Gata-3 in T cells and ILC2s derived from BAL 
of HDM treated mice, as determined by qPCR. At the same time point, the number of IL-13+ 
ILC2s and IL-5+ ILC2s (D) and geometric expression of IL-13 and IL-5 in ILC2s (E) in the 
BAL was assessed by flow cytometry. Figures present combined data from 2 independent 
experiments with 4-6 mice per group in each experiment (B, D and E), or from one experiment 
whereby each data point represents cells pooled from 3 independent mice (C). Results depicted 
as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 using Mann–Whitney 
statistical test. 
 
Figure 3: HDM exposed, neutrophil depleted mice exhibit augmented monocytosis, dendritic 
cell numbers and antigen presentation. 
Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 1 week. 
At 24 hours prior to each HDM/PBS administration, mice were treated with either 100 µg of 
neutrophil depleting antibody, 1A8, or isotype control antibody, 2A3 intraperitoneally (i.p). At 
24 hours post final HDM/PBS exposure, lung tissue was collected. (A) Lung monocyte subsets 
identified as Ly6Clow and Ly6Chigh were enumerated by flow cytometry. (B) Numbers of lung 
monocyte-derived dendritic cells (moDCs) were also determined by flow cytometry. The 
number of moDCs (C) and CD86+ moDCs (D) in the mediastinal lymph nodes (MLN) were 
enumerated by flow cytometry. In some experiments, the final dose of HDM was admixed with 
100 µg Alexa Fluor 488 labelled OVA (E) and mediastinal lymph nodes collected (Ŧ) at 24 hrs 
post the final HDM/PBS exposure. (F) The number of OVA+ moDCs within the mediastinal 
lymph nodes were enumerated by flow cytometry. Figures present data combined from 2 
47 
 
independent experiments with 4-6 mice per group for each experiment (A-D) or from 1 
experiment with 5 mice per group (F). Results depicted as mean ± SEM. *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001 using Mann–Whitney statistical test. 
 
Figure 4: Neutrophil depleted mice display increased numbers of monocyte and dendritic cell 
progenitors within their bone marrow owing to a dysregulated IL-23 – IL-17 – G-CSF axis. 
Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 1 week. 
At 24 hours prior to each HDM/PBS administration, mice were treated with either 100 µg of 
neutrophil depleting antibody, 1A8, or isotype control antibody, 2A3 intraperitoneally (i.p). At 
24 hours post final HDM/PBS exposure, BALF, lung tissue, blood and bone marrow were 
collected. (A) The number of Ly6Clow and Ly6Chigh monocytes in the blood were quantified by 
flow cytometry. (B) The percentage of monocyte dendritic cell progenitors (MDPs) and 
common dendritic cell progenitors (CDPs) within the bone marrow were assessed by flow 
cytometry. (C) The concentration of G-CSF in the serum, lung homogenate and BALF was 
determined by ELISA.  Expression of Csf3 (G-CSF gene; D), Il17 (E) and Il23 (F) was assessed 
in whole lung by qPCR. (G) Schematic depicting the negative feedback pathway by which 
tissue neutrophils limit granulopoiesis by modulation of the IL-23 – IL-17 – G-CSF axis. 
Figures present data from 2 independent experiment with 4-6 mice per group in each 
experiment. Results depicted as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 
using Mann–Whitney statistical test. 
 
Figure 5: Neutralization of G-CSF abrogates the augmented monocytes, bone marrow 
progenitors and TH2 cytokines observed in neutrophil depleted HDM exposed mice.  
 (A) Balb/c mice were administered HDM intranasally (i.n.) 3 times per week for 1 week. At 
24 hours prior to each HDM administration, mice were treated with either 100 µg of neutrophil 
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depleting antibody, 1A8, or isotype control antibody, 2A3. To neutralize G-CSF, mice were 
also administered 100 µg anti-G-CSF or isotype control, 2A3, i.p. at 24 hours prior to each 
HDM dose. At 24 hours post final HDM administration, BAL, lung tissue and bone marrow 
were collected (Ŧ). The number of lung and airway neutrophils (B) and lung Ly6Clow and 
Ly6Chigh monocytes (C) were determined by flow cytometry. (D) The percentage of MDPs and 
CDPs within the bone marrow were assessed by flow cytometry. (E) The concentrations of 
BALF IL-4, IL-5 and IL-13 were assessed by ELISA. (F) Geometric mean of IL-13 by lung 
ILC2s was assessed by flow cytometry. Figures present data combined from 2 independent 
experiments with 4-6 mice per group in each experiment. Results depicted as mean ± SEM. 
*P<0.05, **P<0.01, ***P<0.001 using Mann–Whitney statistical test. 
 
Figure 6: Co-administration of recombinant G-CSF augments numbers of HDM-induced 
neutrophils, monocytes and bone marrow progenitors and ILC2 cytokine responses.   
(A) Balb/c mice were administered PBS or HDM intranasally (i.n.) 3 times per week for 1 
week. Mice were also administered 100 ng recombinant G-CSF i.n. (in 50 µl PBS) and 2 µg 
recombinant G-CSF i.p. (in 2000 µl PBS), or respective PBS controls, daily throughout the 
study. At 24 hours post final HDM administration, BAL, lung tissue and bone marrow were 
collected (Ŧ). The number of lung and airway neutrophils (B) and lung Ly6Clow and Ly6Chigh 
monocytes (C) were determined by flow cytometry. (D) The percentage of MDPs and CDPs 
within the bone marrow were assessed by flow cytometry. (E) The concentrations of BALF IL-
4, IL-5 and IL-13 were assessed by ELISA. (F) Geometric mean of IL-13 by BAL ILC2s was 
assessed by flow cytometry. Figures present data from 1 experiment with 4-6 mice per group 
in each experiment. Results depicted as mean ± SEM. *P<0.05, **P<0.01 using Mann–
Whitney statistical test. 
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Figure 7: G-CSF augments TH2 cytokine production from IL-33 expanded airway Csf3r-
expressing ILC2s.  
Balb/c mice were administered HDM intranasally (i.n.) 3 times per week for 1 week. At 24 
hours post final HDM administration, BAL was collected.  (A) Relative expression of mRNA 
Csf3r in T cells and ILC2s isolated by FACS from the BAL of HDM exposed mice, as 
determined by qPCR. (B) Balb/c mice were administered 1 µg recombinant IL-33 i.n. 3 times 
per week for 1 week. At 24 hours post final IL-33 administration, BAL was collected. (C) 
Relative expression of mRNA Csf3r in T cells and ILC2s isolated by FACS from the BAL of 
IL-33 exposed mice, as determined by qPCR. In some experiments, 100 ng recombinant G-
CSF was co-administered with IL-33 (B), and CD4+ T cells and ILC2s were isolated from the 
airways by FACS, at 24 hours post final IL-33 administration, for subsequent mRNA gene 
expression analysis. (D) Relative expression of IL-4, and IL-13 in T cells and ILC2s derived 
from BAL, as determined by qPCR. (E) From the same experiments, BALF concentrations of 
IL-5 and IL-13 were determined by ELISA. Figures present data from 1 experiment with 4-6 
mice per group in each experiment. Results depicted as mean ± SEM. *P<0.05, **P<0.01 using 
Mann–Whitney statistical test. 
 
Figure 8: G-CSF directly augments TH2 cytokine production from human ILC2s.  
(A) Human ILC2s were isolated from peripheral blood and expanded in bulk culture with IL-
7 (5 ng/ml) and IL-33 (15 ng/ml), before the addition of media or media containing 100 ng/ml 
recombinant G-CSF for 72 hours. (B) Relative expression of CSF3R was assessed by qPCR 
after 72 hours. (C) The levels of IL-5 and IL-13 in the ILC2 supernatant were assessed by a 
multiplex cytokine assay and expressed as a donor specific fold change after G-CSF treatment. 
(D) Expression of IL5, IL13, and GATA3 was assessed by qPCR after 72 hours, and presented 
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as a donor specific fold change after G-CSF treatment. Results depicted as mean ± SEM. 











































































































































































































Title: Neutrophils restrain allergic airway inflammation by limiting ILC2 function and 
monocyte-dendritic cell antigen presentation. 
 
Authors:  
Dhiren F. Patel, Teresa Peiró, Nicoletta Bruno, Juho Vuononvirta, Samia Akthar, Franz Puttur, 
Chloe J. Pyle, Kornelija Suveizdytė, Simone A. Walker, Leo M. Carlin, Lisa G. Gregory, Clare 
M. Lloyd, Robert J. Snelgrove. 
 
 



















Supplementary Fig. 1: Intranasal administration of HDM induces neutrophilic inflammation in 
the lungs and airways of mice. 
(A) Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times a week for up to 3 
weeks, and broncho-alveolar lavage fluid (BALF) and lung tissue collected (Ŧ) at 24 hrs, 1 
week and 3 week time points. The number and percentage of eosinophils and neutrophils in the 
lung tissue (B and C, respectively) and BAL (D and E, respectively) were quantified by flow 
cytometry. (F) Kc expression was assessed in lung by qPCR. (G and H) Levels of KC in lung 
homogenate and BALF were assessed by ELISA at each time point. (I) Csf3 (G-CSF gene) 
expression was assessed in lung by qPCR. (J and K) Levels of G-CSF in lung homogenate and 
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BALF were assessed by ELISA at each time point. Figures present combined data from 2 
independent experiments with 4-6 mice per group in each experiment. Results depicted as mean 
























Supplementary Fig. 2: Intranasal administration of HDM induces an increase in neutrophil 
proteases in the lungs and airways of mice. 
Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times a week for up to 3 
weeks, and broncho-alveolar lavage fluid (BALF) and lung tissue collected at 24 hrs, 1 week 
and 3 week time points. Levels of myeloperoxidase (MPO; A and B) and matrix 
metalloproteinase-9 (MMP-9; C and D) in lung homogenate and BALF were assessed by 
ELISA at each time point.  Figures present combined data from 2 independent experiments 
with 4-6 mice per group in each experiment. Results depicted as mean ± SEM. *P<0.05, 





Supplementary Fig. 3: Intraperitoneal administration of anti-Ly6G antibody, 1A8, systemically 
depletes neutrophils in HDM treated mice.  
(A) Balb/c mice were administered different doses of anti-Ly6G antibody, 1A8, either 
intraperitoneally (i.p) or intranasally (i.n.). After 24 hours mice were administered i.n. 
HDM/PBS, and after a further 24 hours lung tissue, BALF, blood, spleen and bone marrow 
were collected (Ŧ). (B) Flow cytometry gating strategy to identify neutrophils independently 
of Ly6G expression, whereby neutrophils were defined as 
CD11bhighCD11clowF480lowLy6Cintermediate – with validation of population demonstrated in 
figure by Ly6G expression. The number of neutrophils in the lung (C) and BAL (D) were 
determined by flow cytometry. (E) Representative flow cytometry plots demonstrating 
effective neutrophil depletion in lung and airways of mice administered 1A8. The number of 
neutrophils in the blood (F), spleen (G) and bone marrow (H) were enumerated by flow 
cytometry. (I) Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week 
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for up to 3 weeks, and at 24 hours prior to each HDM administration, mice were dosed with 
either 100 µg of neutrophil depleting antibody, 1A8, or isotype control antibody, 2A3, i.p.. At 
24 hours, 1 week and 3 week time points (Ŧ), the number of neutrophils were determined in 
blood (J) and bone marrow (K) by flow cytometry. Figures represent data 1 experiment with 
4-6 mice per group. Results depicted as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 using 





























Supplementary Fig. 4: Intraperitoneal administration of anti-Ly6G antibody, 1A8, specifically 
depletes neutrophils.  
Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 1 week, 
and at 24 hours prior to each HDM/PBS administration mice were dosed with either 100 µg of 
neutrophil depleting antibody, 1A8, or isotype control antibody, 2A3 intraperitoneally (i.p.). 
At 24 hours post final HDM/PBS exposure, bone marrow, blood and lung tissue was collected. 
Representative histogram overlays are presented depicting Ly6G expression on neutrophils, 
eosinophils, Ly6Clow monocytes, Ly6Chigh monocytes and lymphocytes in bone marrow (A), 
blood (B) and lung tissue (C) of PBS and HDM treated mice. Orange = FMO; Blue = PBS; 
Red = HDM. Total numbers of neutrophils, eosinophils, Ly6Clow monocytes and Ly6Chigh 
monocytes in bone marrow (D), blood (E) and lung tissue (F) of PBS and HDM treated mice 
after 2A3 / 1A8 treatment. Figures represent data 1 experiment with 4-6 mice per group. Results 




Supplementary Fig. 5: Neutrophil depleted mice display augmented type 2 inflammation, 
epithelial remodelling and airway resistance after 3 weeks of HDM exposure. 
Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks, 
and at 24 hours prior to each HDM/PBS administration mice were dosed with either 100 µg of 
neutrophil depleting antibody, 1A8, or isotype control antibody, 2A3 intraperitoneally (i.p.). At 
24 hours post final HDM/PBS exposure blood, lung tissue and BALF was collected. (A) Total 
cell numbers in the airways were assessed by trypan blue exclusion. (B) The number of 
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eosinophils in the airways were quantified by flow cytometry. (C) The number of CD4+ T cells 
expressing T1ST2 in the airways were assessed by flow cytometry. (D) Concentrations of total 
IgE and IgG1 in the serum were determined by ELISA. (E) Expression of Muc5ac was 
determined in lung tissue of mice by qPCR. Concentrations of MUC5AC (F) and IL-13 (G) 
protein were assessed in and BALF by ELISA. (H) Correlation between BALF IL-13 and 
MUC5AC concentration for all HDM groups. Airway resistance (R) at baseline was assessed 
by Flexivent (I) and correlated with BALF MUC5AC concentration for all HDM groups (J). 
Figures present combined data from 2 independent experiments with 4-6 mice per group in 
each experiment. Results depicted as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001 using Mann–Whitney statistical test. Correlation analysis was performed using 






Supplementary Fig. 6: Neutrophil depleted mice display comparable airway 
hyperresponsiveness after 3 weeks of HDM exposure. 
Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks, 
and at 24 hours prior to each HDM/PBS administration mice were dosed with either 100 µg of 
neutrophil depleting antibody, 1A8, or isotype control antibody, 2A3 intraperitoneally (i.p.). 
(A) Airway Resistance (R) to increasing doses of methacholine (Mch) was measured 24 hrs 
post the final HDM/PBS exposure. (B) Airway resistance at 100 mg/ml Mch. (C) Lung 
compliance (C) to increasing doses of Mch was measured 24 hrs post the final HDM/PBS 
exposure. Lung compliance at baseline (D) and 100 mg/ml Mch (E). (F) Tissue elastance (E) 
to increasing doses of Mch was measured 24 hrs post the final HDM/PBS exposure. Tissue 
elastance at baseline (G) and 100 mg/ml Mch (H). Figures present combined data from 2 
70 
 
independent experiments with 4-6 mice per group in each experiment. Results depicted as mean 















Supplementary Fig. 7: Augmented TH2 cytokine levels in neutrophil depleted mice 
administered HDM for 1 week.  
Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 1 week 
and at 24 hours prior to each HDM treatment, mice were dosed with either 100 µg of neutrophil 
depleting antibody, 1A8, or isotype control antibody, 2A3 intraperitoneally (i.p.).  At 24 hours 
post the final HDM administration BAL cells and lung tissue were collected.  (A) Expression 
of Il4, Il5 and Il13 were determined in BAL-derived cells by qPCR. (B) Concentrations of IL-
4, IL-5 and IL-13 protein were assessed in lung homogenate by ELISA. (C) Expression of Il4, 
Il5 and Il13 were determined in whole lung by qPCR. Figures present combined data from 1 
experiment with 4-6 mice per group (A) or from 2 independent experiments with 4-6 mice per 
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group in each experiment (B and C). Results depicted as mean ± SEM. *P<0.05, **P<0.01, 


















Supplementary Fig. 8: ILC2s are the predominant source of IL-13 after 1 week of HDM 
administration.  
Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 1 week. 
(A) Gating strategy utilized in some experiments to isolate lung CD45+ leukocytes, CD45-
EpCAM+ epithelial cells and CD45-EpCAM-CD31+ endothelial cells by fluorescence-activated 
cell sorting (FACS) at 24 hours post the final PBS / HDM administration. (B) Relative 
expression of Il4, Il5 and Il13 was determined in isolated populations by qPCR. Female IL-13 
gfp-reporter mice were administered HDM intranasally (i.n.) 3 times per week for 1 week. At 
24 hours post final HDM exposure, BALF was collected to identify IL-13+ cell populations by 
flow cytometry. (C) Representative contour plots depicting IL-13 expression by airway ILCs, 
CD4+ T cells, eosinophils and CD11c+ macrophages. Figures present data from 1 experiment 






Supplementary Fig. 9: Gating strategy for isolation of ILC2s and CD4+ T cells by fluorescence 
activated cell sorting.  
A gating strategy was deployed to sort ILC2s and CD4+ T cells independent of intracellular 
cytokine staining. Total live cells were assessed for CD45 to isolate live leukocytes. 
Leukocytes were subsequently interrogated for the expression of common lineage markers in 
a self-made lineage cocktail (TCRβ, CD5, CD19, TCRγδ, CD11b, CD11c, FCεR1, GR-1, 
F4/80, TER-119 and NKp46) with CD4+ T cells being identified as Lin+ CD4+. Lineage 
negative cells were interrogated for the expression of ICOS and ILC2-defining maker, KLRG1, 














Supplementary Fig. 10: Augmented IL-5 and IL-13 levels in lungs of neutrophil depleted mice 
administered HDM for 1 week are primarily derived from ILC2s.  
Balb/c mice were administered HDM intranasally (i.n.) 3 times per week for 1 week and at 24 
hours prior to each HDM treatment, mice were dosed with either 100 µg of neutrophil depleting 
antibody, 1A8, or isotype control antibody, 2A3 intraperitoneally (i.p.).  At 24 hours post the 
final HDM exposure, CD4+ T cells and ILC2s were isolated from lung tissue by fluorescence 
activated cell sorting (FACS) for subsequent mRNA gene expression analysis. Relative 
expression of IL-4, IL-5, IL-13 and GATA-3 in T cells and ILC2s derived from lung tissue, as 
determined by qPCR. Figures present data from 1 experiment with 5 mice per group. Results 





Supplementary Fig. 11: ILC2s from neutrophil depleted mice administered HDM for 1 week 
produce more IL-5 and IL-13 on a per cell basis.  
Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 1 week 
and at 24 hours prior to each HDM treatment, mice were dosed with either 100 µg of neutrophil 
depleting antibody, 1A8, or isotype control antibody, 2A3 intraperitoneally (i.p.).  (A) At 24 
hours post final PBS/HDM administration, the total number of ILC2s in lung tissue and BAL 
was determined by flow cytometry. The percentage of lung and BAL ILC2s producing IL-5 
(B) and IL-13 (C) were determined by flow cytometry. (D) The number of IL-13+ ILC2s and 
geometric expression of IL-13 on ILC2s in the lung was assessed by flow cytometry. (E) 
Similarly, the number of IL-5+ ILC2s and geometric mean of IL-5 on ILC2s in the lung was 
assessed by flow cytometry. (F) Representative contour plots depicting IL-13 and IL-5 
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expression by ILC2s from the lungs of mice administered HDM for 1 week in combination 
with 2A3 or 1A8. Figures present data from 2 independent experiments with 4-6 mice per group 
in each experiment (A, C and D) or from 1 experiment with 4-6 mice per group (B and E). 
















Supplementary Fig. 12: HDM exposed, neutrophil depleted mice exhibit augmented dendritic 
cell numbers and antigen presentation. 
Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 1 week. 
At 24 hours prior to each HDM/PBS administration, mice were treated with either 100 µg of 
neutrophil depleting antibody, 1A8, or isotype control antibody, 2A3 intraperitoneally (i.p). At 
24 hours post final HDM/PBS exposure, lung tissue and mediastinal lymph nodes (MLNs) 
were collected. (A) Representative images of precision cut lung slices from control and 
neutrophil depleted mice exposed to HDM for 1 week, showing monocytes (CD115; magenta), 
airway macrophages (CD11c; yellow), neutrophils (Ly6G; red) and endothelial cells (CD31; 
white). Airways (A) and blood vessels (BV) are annotated. (B) Numbers of lung CD11b+ 
conventional dendritic cells (CD11b+ cDCs) and CD103+ cDCs were determined by flow 
cytometry. The number of mediastinal lymph node (MLN) CD11b+ cDCs (C), CD86+ CD11b+ 
cDCs (D), were enumerated by flow cytometry. In some experiments, the final dose of HDM 
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was admixed with 100 µg Alexa Fluor 488 labelled OVA and MLNs collected at 24 hrs post 
the final HDM/PBS exposure. (E) The number of OVA+ CD11b+ cDCs in the MLNs were 
determined by flow cytometry. MLN CD4+ T cell geometric mean expression of ICOS (F) and 
PD-1 (G), and the number of Ki-67+ CD4+ T cells (H) were also enumerated by flow cytometry. 
Figures present data combined from 2 independent experiments with 4-6 mice per group for 
each experiment (B-D and F-H) or from 1 experiment with 5 mice per group (E). Results 
depicted as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001; ****P<0.0001 using Mann–









Supplementary Fig. 13: Lung concentrations of classical monocyte chemokines and flow 
cytometry gating strategy to identify monocyte dendritic cell progenitors (MDPs) and common 
dendritic cell progenitors (CDPs).  
(A) Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 1 
week. At 24 hours prior to each HDM/PBS administration, mice were treated with either 100 
µg of neutrophil depleting antibody, 1A8, or isotype control antibody, 2A3 intraperitoneally 
(i.p). At 24 hours post final HDM/PBS exposure, lung tissue was collected. The concentration 
of CCL2 and CX3CL1 in lung homogenate was assessed by ELISA. Figures present data 
combined from 2 independent experiments with 4-6 mice per group for each experiment. 
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Results depicted as mean ± SEM. **P<0.01, ***P<0.001; ****P<0.0001 using Mann–
Whitney statistical test. (B) A gating strategy was deployed to enumerate MDPs and CDPs in 
bone marrow by flow cytometry. Total live cells were assessed for CD115 expression, with 
CD115+ cells subsequently further interrogated for expression of common leukocyte markers 
in a lineage cocktail (CD3, CD19, SiglecF, Ly6G, NKp46 and CD90.2). CD115+Lin- cells were 
then interrogated for relative expression of c-Kit and FLT3, with c-Kit+FLT3+ defined as 
MDPs. Cells that were c-Kit-FLT3+ were further analysed for expression of CD11c and CD11b, 




Supplementary Fig. 14: G-CSF is elevated in the serum of neutrophil depleted mice 
administered HDM. 
Balb/c mice were administered HDM intranasally (i.n.) 3 times per week for 1 week. At 24 
hours prior to each HDM administration, mice were treated with either 100 µg of neutrophil 
depleting antibody, 1A8, or isotype control antibody, 2A3, intraperitoneally (i.p).  At 24 hours 
post final HDM exposure, serum was collected for proteome profiler analysis. (A) Images of 
the proteome profiler blots from control and neutrophil depleted mice administered HDM for 
1 week. Red boxes denote the position of G-CSF on respective blots. (B) Fold change in serum 
83 
 
cytokine pixel density in HDM-exposed neutrophil depleted mice over respective control mice. 
(C) Fold change in serum chemokine and protease pixel density in HDM-exposed neutrophil 






Supplementary Fig. 15: Neutrophil depleted mice administered HDM produce elevated levels 
of IL-17 and IL-23.  
Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 1 week. 
At 24 hours prior to each HDM/PBS administration, mice were treated with either 100 µg of 
neutrophil depleting antibody, 1A8, or isotype control antibody, 2A3 intraperitoneally (i.p). At 
24 hours post final HDM/PBS exposure, lung tissue was collected. (A) Il17 expression was 
determined in isolated lung populations of CD4+ T cell and ILC2s by qPCR. (B) The number 
of lung IL-17+ CD4+ T cells and IL-17+ γδ T cells were determined by flow cytometry. (C) 
Representative contour plots depicting IL-17 expression by CD4+ T cells and IL-17+ γδ T cells 
from 2A3 and 1A8 treated mice after 1 week of HDM administration. (D) The number of lung 
IL-23+ CD11c+ macrophages and IL-23+ moDCs were determined by flow cytometry. (E) 
Geometric mean of IL-23 expression by CD11c+ macrophages and moDCs as adjudged by flow 
cytometry.  (F) Representative histogram overlays of IL-23 expression by CD11c+ 
macrophages and moDCs. Histogram overlay for IL-23 expression by T cells is also presented 
to demonstrate specificity of binding of the anti-IL-23 antibody. Grey = FMO; Red = 
HDM/2A3; Blue = HDM/1A8. Figures present data from 1 experiment with 5 mice per group 
(A) or from 2 independent experiment with 4-6 mice per group in each experiment (B, D and 
E). Results depicted as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 using 





Supplementary Fig. 16: Neutralization of IL-17 reverts the effects of neutrophil depletion in 
HDM administered mice.  
Balb/c mice were administered HDM intranasally (i.n.) 3 times per week for 1 week. At 24 
hours prior to each HDM administration, mice were treated with either 100 µg of neutrophil 
depleting antibody, 1A8, or isotype control antibody, 2A3. To neutralize IL-17, mice were also 
administered 20 µg anti-IL-17 or isotype control, 2A3, i.p. at 24 hours prior to each HDM dose. 
At 24 hours post final HDM administration, serum, lung tissue, BAL and bone marrow were 
collected. (A) The concentrations of G-CSF in serum, lung homogenate and BALF were 
assessed by ELISA. (B) The number of neutrophils in the lung and BAL were determined by 
flow cytometry. (C) The number of lung Ly6Clow and Ly6Chigh monocytes were determined by 
flow cytometry. (D) The percentage of monocyte dendritic cell progenitors (MDPs) and 
common dendritic cell progenitors (CDPs) within the bone marrow were assessed by flow 
cytometry. (E) Geometric mean of IL-13 and IL-5 expression by airway ILCs was assessed by 
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flow cytometry. Figures present data from 1 experiment with 4-6 mice per group Results 


















Supplementary Fig. 17: G-CSF directly augments TH2 cytokine production from mouse ILC2s.  
(A) Balb/c mice were administered 1 µg recombinant IL-33 i.n. 3 times per week for 1 week. 
At 24 hours post final IL-33 administration, lungs were collected and ILC2s isolated by 
fluorescence activated cell sorting.  ILC2s were subsequently cultured with combinations of 
IL-7 (5ng/ml) / IL-33 (10 ng/ml) and /or recombinant G-CSF (10 or 100 ng/ml), as depicted 
within the figure, for 72 hours. (B) The levels of IL-5 and IL-13 in the ILC2 supernatant were 
assessed by ELISA. (C) Relative expression of Il5, Il13, and Gata3 was assessed by qPCR 
after 72 hours. Results depicted as mean ± SEM. *P<0.05 using an ANOVA test followed by 






Supplementary Fig. 18: Neutrophil depletion alters the IL-23 – IL-17 – G-CSF regulatory 
feedback pathway to exacerbate TH2 cytokine production and allergen sensitisation.  
Inset: Lung CD11c+ macrophages produce IL-23, which functions to promote IL-17 production 
by CD4+ and γδ T cells. IL-17 subsequently induces G-CSF production, which drives 
neutrophil granulopoiesis and efflux from the bone marrow. Neutrophils transmigrate into an 
allergen exposed lung, before undergoing apoptosis and being phagocytosed by resident 
macrophages, whose IL-23 production is subsequently diminished. In the absence of tissue 
neutrophils, this feedback cycle becomes dysregulated giving rise to increased IL-23, IL-17 
and G-CSF. Main Figure:  In an allergen exposed lung, accumulated G-CSF acts on the 
expanded ILC2 population to promote their IL-5 and IL-13 production. Concomitantly, G-CSF 
drives the expansion of bone marrow progenitors, MDPs and CDPs, leading to a monocytosis 
and increase in lung moDCs. The increased population of moDCs sample allergen, become 
activated and migrate to the local draining mediastinal lymph node to activate T cells in the 
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context of the heightened TH2 cytokine milieu. This ultimately results in augmented TH2 




















Supplementary Table 1: Raw data file. See uploaded document.  
 
Supplementary Table 2: List of antibodies utilised for flow cytometry staining. 
Cell type 
Surface marker 
phenotype Monoclonal antibody conjugate Dilution 
Neutrophils 
CD11bhigh CD11b-PerCP (ThermoFisher Scientific) 1/400 
CD11c- CD11c-APC (BD Biosciences) 1/200 
F480- F4/80-PE (ThermoFisher Scientific) 1/50 
Ly6Ghigh Ly6G-FITC (BD Biosciences) 1/100 
Ly6Cint Ly6C-PE-Cy7 (BD Biosciences) 1/100 
Eosinophils 
CD11bhigh CD11b-PerCP (ThermoFisher Scientific) 1/400 
CD11clow CD11c-APC (BD Biosciences) 1/200 
SiglecFhigh SiglecF-BV421 (Biolegend) 1/200 
Ly-6Glow Ly6G-FITC (BD Biosciences) 1/100 
Alveolar 
macrophages 
CD11b- CD11b-PerCP (eBioscience) 1/400 
CD11c+ CD11c-APC (BD Biosciences) 1/200 
F4/80high F4/80-PE (eBioscience) 1/50 




CD3-PE, CD19-PE, CD90.2-PE, Nkp46-
PE, Ly6G-PE, Siglec-F-PE (ThermoFisher 
Scientific) 
1/100 
CD11b+ CD11b-PerCP (ThermoFisher Scientific) 1/400 
CD11c- CD11c-FITC (BD Biosciences) 1/100 
F4/80high F4/80-PE-DAZZLE (Biolegend) 1/50 
Ly6Chigh Ly6C-Alexa Fluor 700 (Biolegend) 1/200 
Further confirmed 




CD3-PE, CD19-PE, CD90.2-PE, Nkp46-
PE, Ly6G-PE, Siglec-F-PE (ThermoFisher 
Scientific) 
1/100 
CD11b+ CD11b-PerCP (ThermoFisher Scientific) 1/400 
CD11c- CD11c-FITC (BD Biosciences) 1/100 
F4/80high F4/80-PE-DAZZLE (Biolegend) 1/50 
Ly6Clow Ly6C-Alexa Fluor 700 (Biolegend) 1/200 
Further confirmed 




CD3-PE, CD19-PE, CD90.2-PE, Nkp46-
PE, Ly6G-PE, Siglec-F-PE (ThermoFisher 
Scientific) 
1/100 
CD11c+ CD11c-FITC (BD Biosciences) 1/100 
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CD11bhigh CD11b-PerCP (ThermoFisher Scientific) 1/400 
CD103- CD103-APC (Biolegend) 1/100 
MHCIIhigh I-A/I-E-BV421 (Biolegend) 1/200 
CD64+ CD64-PE-Cy7 1/50 
CD11b+ cDCs 
Myeloid Lin- 
CD3-PE, CD19-PE, CD90.2-PE, Nkp46-
PE, Ly6G-PE, Siglec-F-PE (ThermoFisher 
Scientific) 
1/100 
CD11c+ CD11c-FITC (BD Biosciences) 1/100 
CD11bhigh CD11b-PerCP (ThermoFisher Scientific) 1/400 
CD103- CD103-APC (Biolegend) 1/100 
MHCIIhigh I-A/I-E-BV421 (Biolegend) 1/200 
CD64- CD64-PE-Cy7 1/50 
CD103+ cDCs 
Myeloid Lin- 
CD3-PE, CD19-PE, CD90.2-PE, Nkp46-
PE, Ly6G-PE, Siglec-F-PE (ThermoFisher 
Scientific) 
1/100 
CD11c+ CD11c-FITC (BD Biosciences) 1/100 
CD11b- CD11b-PerCP (ThermoFisher Scientific) 1/400 
CD103+ CD103-APC (Biolegend) 1/100 
MHCIIhigh I-A/I-E-BV421 (Biolegend) 1/200 
CD64- CD64-PE-Cy7 1/50 
MDPs 
Myeloid Lin- 
CD3-PE, CD19-PE, CD90.2-PE, Nkp46-
PE, Ly6G-PE, Siglec-F-PE (ThermoFisher 
Scientific) 
1/100 
CD11c- CD11c-FITC (BD Biosciences) 1/100 
CD115+ CD115-APC (Biolegend) 1/50 
ckit/CD117+ CD117-Pe-CY7 (ThermoFisher Scientific) 1/50 
Flt-3+ CD135-PE-DAZZLE (Biolegend) 1/50 
MHCIIlow I-A/I-E-BV421 (Biolegend) 1/200 
MDPs 
Myeloid Lin- 
CD3-PE, CD19-PE, CD90.2-PE, Nkp46-
PE, Ly6G-PE, Siglec-F-PE (ThermoFisher 
Scientific) 
1/100 
CD11c- CD11c-FITC (BD Biosciences) 1/100 
CD115+ CD115-APC (Biolegend) 1/50 
ckit/CD117- CD117-Pe-CY7 (ThermoFisher Scientific) 1/50 
Flt-3+ CD135-PE-DAZZLE (Biolegend) 1/50 
MHCIIlow I-A/I-E-BV421 (Biolegend) 1/200 
ILCs 
ILC Lin- 
TCRβ-APC, CD5-APC, CD19-APC, 
TCRγδ-APC, CD11b-APC, CD11c-APC, 
FCεR1-APC, GR-1-APC, F4/80-APC, 
TER-119-APC, CD3-APC, Nkp46-APC 
(Biolegend) 
1/100 
ICOS+ CD278/ICOS-PE-Cy7 (Biolegend) 1/100 
KLRG1+ KLRG1-PerCP (Biolegend) 1/50 
CD45+ CD45-BV711 (Biolegend) 1/100 
CD4 T-cells CD3+ CD3-PE-Cy7 (eBioscience) 1/200 
93 
 
CD4+ CD4-PerCP (BD Biosciences) 1/200 
CD8- CD8-APC (BD Biosciences) 1/200 
CD8 T-cells 
CD3+ CD3-PE-Cy7 (eBioscience) 1/200 
CD4- CD4-PerCP (BD Biosciences) 1/200 




CD3-PE, CD19-PE, CD90.2-PE, Nkp46-
PE, Ly6G-PE, Siglec-F-PE (ThermoFisher 
Scientific) 
1/100 
CD11c+ CD11c-FITC (BD Biosciences) 1/100 
CD11bhigh CD11b-PerCP (ThermoFisher Scientific) 1/400 
CD103- CD103-APC (Biolegend) 1/100 
MHCIIhigh I-A/I-E-BV421 (Biolegend) 1/200 
CD64+ CD64-PE-Cy7 (Biolegend) 1/50 
CD86 (to assess 




CD3-PE, CD19-PE, CD90.2-PE, Nkp46-
PE, Ly6G-PE, Siglec-F-PE (ThermoFisher 
Scientific) 
1/100 
CD11c+ CD11c-FITC (BD Biosciences) 1/100 
CD11bhigh CD11b-PerCP (ThermoFisher Scientific) 1/400 
CD103- CD103-APC (Biolegend) 1/100 
MHCIIhigh I-A/I-E-BV421 (Biolegend) 1/200 
CD64- CD64-PE-Cy7 1/50 
CD86 (to assess 
expression) CD86-Alexa Fluor 700 (Biolegend) 1/100 
MLN CD4 T-
cells 
CD3+ CD3-PE-Cy7 (ThermoFisher Scientific) 1/200 
CD4+ CD4-PerCP (BD Biosciences) 1/200 
CD8- CD8-APC (BD Biosciences) 1/200 
ICOS (to assess 
expression) CD278/ICOS-PE-Cy7 (Biolegend) 1/100 
PD1 (to assess 
expression) CD297-PEDAZZLE (Biolegend) 1/100 
Epithelial Cells 
EpCAM+ EpCAM-PE (ThermoFisher Scientific) 1/100 
CD45- CD45-PerCP (ThermoFisher Scientific) 1/100 
CD31- CD31-APC (Biolegend) 1/100 
Endothelial Cells 
EpCAM- EpCAM-PE (ThermoFisher Scientific) 1/100 
CD45- CD45-PerCP (ThermoFisher Scientific) 1/100 
CD31+ CD31-APC (Biolegend) 1/100 
Human ILC 
enrichment 
Lin- Lin-FITC (ThermoFisher Scientific) 1/30 
CD45+ CD45-PerCP (ThermoFisher Scientific) 1/100 
CRTH2+ CRTH2-BV421 (Biolegend) 1/100 
 
 
 
